

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSET TRANSFER AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
ELAN PHARMA INTERNATIONAL LIMITED	08/02/2011
RECEIVING PARTY DATA	
Name:	EDT PHARMA HOLDINGS LIMITED
Street Address:	MONKSLAND
Internal Address:	ATHLONE
City:	COUNTY WESTMEATH
State/Country:	IRELAND
PROPERTY NUMBERS Total: 30	
Property Type	Number
Patent Number:	5643552
Patent Number:	5472683
Patent Number:	5573749
Patent Number:	5488133
Patent Number:	5500204
Patent Number:	5503723
Patent Number:	5510118
Patent Number:	5518187
Patent Number:	5518738
Patent Number:	5521218
Patent Number:	5525328
Patent Number:	5534270
Patent Number:	5543133
Patent Number:	5571536
Patent Number:	5560931

OP \$1200.00 5643552

Patent Number:	5560932
Patent Number:	5565188
Patent Number:	5705194
Patent Number:	5569448
Patent Number:	5573750
Patent Number:	5573783
Patent Number:	5580579
Patent Number:	5585108
Patent Number:	5587143
Patent Number:	5591456
Patent Number:	5593657
Patent Number:	5603916
Patent Number:	5622938
Patent Number:	5628981
Patent Number:	6432381

CORRESPONDENCE DATA

Fax Number: 2026725399
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 202-672-5300
 Email: swalker@foley.com
 Correspondent Name: Michele M. Simkin
 Address Line 1: Foley & Lardner LLP
 Address Line 2: 3000 K Street, NW, Suite 600
 Address Line 4: Washington, DISTRICT OF COLUMBIA 20007

ATTORNEY DOCKET NUMBER:	029318-2340
-------------------------	-------------

NAME OF SUBMITTER:	Michele M. Simkin
--------------------	-------------------

Total Attachments: 82

source=Asset_Agreement#page1.tif
 source=Asset_Agreement#page2.tif
 source=Asset_Agreement#page3.tif
 source=Asset_Agreement#page4.tif
 source=Asset_Agreement#page5.tif
 source=Asset_Agreement#page6.tif
 source=Asset_Agreement#page7.tif
 source=Asset_Agreement#page8.tif
 source=Asset_Agreement#page9.tif
 source=Asset_Agreement#page10.tif
 source=Asset_Agreement#page11.tif
 source=Asset_Agreement#page12.tif
 source=Asset_Agreement#page13.tif

PATENT
REEL: 029043 FRAME: 0480

source=Asset_Agreement#page14.tif
source=Asset_Agreement#page15.tif
source=Asset_Agreement#page16.tif
source=Asset_Agreement#page17.tif
source=Asset_Agreement#page18.tif
source=Asset_Agreement#page19.tif
source=Asset_Agreement#page20.tif
source=Asset_Agreement#page21.tif
source=Asset_Agreement#page22.tif
source=Asset_Agreement#page23.tif
source=Asset_Agreement#page24.tif
source=Asset_Agreement#page25.tif
source=Asset_Agreement#page26.tif
source=Asset_Agreement#page27.tif
source=Asset_Agreement#page28.tif
source=Asset_Agreement#page29.tif
source=Asset_Agreement#page30.tif
source=Asset_Agreement#page31.tif
source=Asset_Agreement#page32.tif
source=Asset_Agreement#page33.tif
source=Asset_Agreement#page34.tif
source=Asset_Agreement#page35.tif
source=Asset_Agreement#page36.tif
source=Asset_Agreement#page37.tif
source=Asset_Agreement#page38.tif
source=Asset_Agreement#page39.tif
source=Asset_Agreement#page40.tif
source=Asset_Agreement#page41.tif
source=Asset_Agreement#page42.tif
source=Asset_Agreement#page43.tif
source=Asset_Agreement#page44.tif
source=Asset_Agreement#page45.tif
source=Asset_Agreement#page46.tif
source=Asset_Agreement#page47.tif
source=Asset_Agreement#page48.tif
source=Asset_Agreement#page49.tif
source=Asset_Agreement#page50.tif
source=Asset_Agreement#page51.tif
source=Asset_Agreement#page52.tif
source=Asset_Agreement#page53.tif
source=Asset_Agreement#page54.tif
source=Asset_Agreement#page55.tif
source=Asset_Agreement#page56.tif
source=Asset_Agreement#page57.tif
source=Asset_Agreement#page58.tif
source=Asset_Agreement#page59.tif
source=Asset_Agreement#page60.tif
source=Asset_Agreement#page61.tif
source=Asset_Agreement#page62.tif
source=Asset_Agreement#page63.tif
source=Asset_Agreement#page64.tif
source=Asset_Agreement#page65.tif
source=Asset_Agreement#page66.tif
source=Asset_Agreement#page67.tif
source=Asset_Agreement#page68.tif

source=Asset_Agreement#page69.tif
source=Asset_Agreement#page70.tif
source=Asset_Agreement#page71.tif
source=Asset_Agreement#page72.tif
source=Asset_Agreement#page73.tif
source=Asset_Agreement#page74.tif
source=Asset_Agreement#page75.tif
source=Asset_Agreement#page76.tif
source=Asset_Agreement#page77.tif
source=Asset_Agreement#page78.tif
source=Asset_Agreement#page79.tif
source=Asset_Agreement#page80.tif
source=Asset_Agreement#page81.tif
source=Asset_Agreement#page82.tif

Dated 2 August 2011

ELAN PHARMA INTERNATIONAL LIMITED
(Vendor)

and

EDT PHARMA HOLDINGS LIMITED
(Purchaser)

ASSET TRANSFER AGREEMENT

for the purchase of the trading assets relating to the Drug Delivery Business of
ELAN PHARMA INTERNATIONAL LIMITED

A & L GOODBODY

THIS ASSET TRANSFER AGREEMENT is dated 2 August 2011 and made between

- (1) **ELAN PHARMA INTERNATIONAL LIMITED** (registered no. 222276) having its registered office at Monksland, Athlone, Co. Westmeath (**Vendor**); and
- (2) **EDT PHARMA HOLDINGS LIMITED** a company incorporated in Ireland (Registered No. 448848) whose registered office is at Treasury Building, Grand Canal Street Lower, Dublin 2 (**Purchaser**).

RECITALS:

- A. The Vendor is carrying on a trade of the purchase, development and exploitation of certain intellectual property rights and is the owner of certain trading assets (including intellectual property rights) relating to the EDT Business.
- B. Under the Business Transfer Agreement, the Purchaser has acquired the manufacturing business forming part of the EDT Business including the employees engaged in connection therewith.
- C. The Vendor has agreed to sell and the Purchaser has agreed to purchase the Trading Assets upon the terms and subject to the conditions of this Agreement and will use these trading assets in the course of its manufacturing business.
- D. As set out in Section 7.1(k) of the Merger Agreement, the Purchaser will, for so long as it is a member of the Elan Tax Group, carry on its business in the same manner as the Vendor and will carry the Trading Assets as trading stock for tax purposes. The Trading Assets under this Agreement should not include any assets relating to the EDT Business other than assets which were held as trading stock by the Vendor.

IT IS HEREBY AGREED as follows:

1. PRELIMINARY

- 1.1. **Definitions:** In this Agreement and in the Schedules unless the context otherwise requires:

1963 Act means the Companies Act, 1963;

1990 Act means the Companies Act, 1990;

Authorisations means those authorisations, licences and permits necessary for the conduct of the EDT Business which are in the name of the Purchaser;

Business Contracts means all contracts, agreements, arrangements and understandings of every kind with customers of the EDT Business and other contracts relating to the EDT Business, which form part of the Trading Assets;

Business Day means any day on which banks are generally open for business in Dublin excluding Saturdays and Sundays;

Business Transfer Agreement means the agreement dated 26 July 2011 pursuant to which the Purchaser has acquired the Manufacturing Business from Elan Science Five Limited;

Completion means completion of the sale and purchase of the Trading Assets pursuant to this Agreement;

Conditions means the pre-conditions to closing listed in clause 3.2;

Confidential Information means any and all information received or obtained as a result of (i) the operation of the EDT Business and/or (ii) entering into or performing, or supplied by or on behalf of a party in the negotiations leading to, this Agreement and which in each case relates to:

- (a) the EDT Business;

- (b) the Manufacturing Business;
- (c) the provisions of this Agreement;
- (d) the negotiations relating to this Agreement;
- (e) the subject matter of this Agreement; or
- (f) the Purchaser or any subsidiary or holding company of the Purchaser;

EDT Business means the suite of activities including: research, development, drug optimization and delivery utilizing Elan's proprietary drug delivery technologies (including its NanoCrystal® technology for poorly water-soluble compounds, and its range of oral controlled release delivery technologies comprising extended, delayed and pulsatile release); drug scale up capabilities including formulation development, analytical development, clinical trial manufacturing and scale-up and product registration support; performing such research and development services for third parties; licensing or otherwise permitting the practice and use by third parties of such Elan proprietary drug delivery technologies or products incorporating such drug delivery technologies; and commercial manufacturing of pharmaceutical dosage forms both for products incorporating Elan proprietary technologies, the Fill/Finish Business and all contract manufacturing carried on by the Vendor;

Effective Date means the date of this Agreement;

Employees means those employees of the Vendor employed in connection with the Trading Assets;

Elan Tax Group means Elan Corporation plc and all of its wholly owned direct and indirect subsidiaries resident for tax purposes in Ireland;

Encumbrance includes, without limitation, any interest or equity of any person (including any right to acquire any option) or any mortgage, charge, pledge, lien, assignment, hypothecation, security interest (including any created by law), title retention or other security agreement or arrangement or a rental, hire purchase, credit sale or other agreement for payment on deferred terms;

Excluded Assets means those assets of the Vendor set out in **Schedule 1** which are not being sold hereunder;

Fill/Finish Business means the fill/finish business carried on by the Vendor at Building 17 on the EDT Business campus at Monkstown Industrial estate, Athlone, Co. Westmeath;

Information means all customer and supplier records and correspondence (including, in each case, the full name and the address and addresses for delivery or collection or for provision of services) relating to the EDT Business, all books of account relating to the EDT Business and other records of the EDT Business for the six years prior to Completion, all deeds and documents evidencing title to the Trading Assets (duly stamped where appropriate), all sales and technical literature and all other documents, computer records and programs relating to or required for the due and efficient carrying on of the EDT Business and all files and other relevant information relating to the Employees;

Intellectual Property means any and all rights pertaining to inventions, discoveries, trade secrets, confidential business information, financial, marketing and business data, concepts, ideas and improvements to existing technology (in each case whether or not written down or otherwise converted to tangible form), patents, patent applications, patent disclosures, designs, trade marks, service marks, trade names, logos, rights in any domain names, algorithms, database rights, goodwill, copyright(s), moral rights, know-how, reputation, modes, get-up, computer programs and analogous property, plans, models, and all other forms of industrial or intellectual property (in each case in any part of the world and whether or not registered or registerable and to the fullest extent thereof and for the full period therefor and all extensions and renewals thereof), all applications for registration of the foregoing and all rights and interest, present and future thereto and therein;

Intellectual Property Rights means such Intellectual Property used exclusively in connection with the EDT Business and such other Intellectual Property as are included in the Trading Assets;

Ireland means Ireland excluding Northern Ireland and Irish will be construed accordingly;

Licence User Agreement means an agreement entered into on today's date by the Vendor and the Purchaser pursuant to which the Vendor agrees to sub-licence the Authorisations to the Purchaser;

Loan Note means the loan note to be issued by the Purchaser in the name of the Vendor in the amount of _____ on Completion pursuant to clause 3.4;

Manufacturing and Supply Agreement means the agreement entered into by Elan Science Five Limited (**ES5**) and the Vendor on 26 July 2011 whereby ES5 has agreed to manufacture and supply to the Vendor certain products and the Vendor has agreed to purchase the products upon the terms set out in the agreement;

Manufacturing Business means all the capital assets, manufacturing assets, real property, fixtures and fittings and all other assets owned by the Vendor, other than the Excluded Assets including the Vendor's obligations under the Manufacturing and Supply Agreement, which are to be acquired by the Purchaser pursuant to the Business Transfer Agreement;

Merger Agreement means the business combination agreement and plan of merger entered into by Elan Corporation, plc, Antler Science Two Limited, Elan Science Four Limited, EDT Pharma Holdings Limited, EDT US Holdco Inc., Antler Acquisition Corp. and Alkermes, Inc. on 9 May 2011;

Patents means the patents listed at Schedule 2 to this Agreement;

Taxation and **Tax** means all forms of taxation, duties, imposts and levies whether of Ireland or elsewhere, including (but without limitation) income tax, corporation tax, corporation profits tax, advance corporation tax, capital gains tax, capital acquisitions tax, residential property tax, wealth tax, value added tax, customs and other import and export duties, excise duties, vehicle registration tax, stamp duty, capital duty, social insurance, social welfare or other similar contributions and other amounts corresponding thereto whether payable in Ireland or elsewhere, and any costs, interest, surcharge, penalty or fine relating to the same and any penalties chargeable for non-compliance with any statutory provisions or regulations in connection therewith and the word **taxation** shall be construed accordingly;

TCA means the Taxes Consolidation Act, 1997;

Termination Letter means a letter dated the date of this Agreement between the Vendor and the Purchaser pursuant to which the Manufacturing and Supply Agreement is to be terminated;

Trading Assets means the assets listed in Clause 2.1 including all the Intellectual Property owned by the Vendor in respect of or related to the EDT Business, other than for the avoidance of doubt the Excluded Assets, all of which are to be acquired by or novated in favour of the Purchaser pursuant to this Agreement; and

VAT means value added tax within the meaning of the Value-Added Tax Consolidation Act 2010.

- 1.2. The Schedules referred to in this Agreement form an integral part of this Agreement, and references to this Agreement include reference to them.
- 1.3. Headings are inserted for convenience only and do not affect the construction of this Agreement.
- 1.4. All references in this Agreement to costs, charges or expenses include any value added tax or similar tax charged or chargeable on them.
- 1.5. Unless expressly stated in this Agreement or the context otherwise requires, in this Agreement:
 - 1.5.1. references to persons are deemed to include references to natural persons, firms, partnerships, companies, corporations, associations, bodies corporate, trusts and investment funds (in each case whether or not having a separate legal personality) but references to individuals are deemed to be references to natural persons only;
 - 1.5.2. words importing the singular include the plural and vice versa and words importing the masculine include references to the feminine and neuter and vice versa;
 - 1.5.3. reference to writing or similar expressions includes transmission by facsimile or electronic means;

- 1.5.4. a word or phrase the definition of which is contained or referred to in section 2 of the 1963 Act has the meaning attributed to it by that definition;
- 1.5.5. references to Acts, statutory instruments and other legislation are to legislation operative in Ireland and to such legislation, modified, consolidated, amended or re-enacted (whether before or after the date of this Agreement) and any subordinate legislation made under that legislation;
- 1.5.6. reference to any Irish legal term, concept, legislation or regulation (including, those for any action, remedy, method of judicial proceeding, document, statute, court official, governmental authority or agency) or any accounting term or concept, in respect of any jurisdiction other than Ireland will be construed as a reference to the term or concept which most nearly corresponds to it in that jurisdiction;
- 1.5.7. reference to this Agreement includes this Agreement as amended or supplemented from time to time; and
- 1.5.8. "including" and "includes" mean including or includes without limiting the generality of the foregoing.

2. SALE OF ASSETS

- 2.1. **Sale and Purchase:** Subject to the terms of this Agreement, the Vendor shall sell as legal and beneficial owner and the Purchaser shall purchase in reliance on the provisions of this Agreement free from all Encumbrances and together with all rights now or hereafter attaching thereto, the Trading Assets including:

- 2.1.1. the Patents;
- 2.1.2. the Intellectual Property Rights
- 2.1.3. subject to clause 4 the full benefit subject to the burden (so far as the same is capable of assignment) of the Business Contracts and all of the Vendor's pending contracts engagements and all orders in connection with the EDT Business;
- 2.1.4. the Authorisations;
- 2.1.5. any related goodwill of the EDT Business and to represent the Purchaser as carrying on the EDT Business in continuation of that carried on by the Vendor and in succession thereto;
- 2.1.6. the Information; and
- 2.1.7. all other property in connection with the Intellectual Property Rights except the Excluded Assets.

- 2.2. **Other Benefits:**

- 2.2.1. If the Vendor receives any sums or benefits in respect of any of the Trading Assets it shall forthwith pay or cause to be paid (as the case may be) to the Purchaser as soon as practicable and in any event within ten Business Days of receipt thereof to a bank account to be nominated by the Purchaser it being recognised and agreed by the Vendor that, if the Purchaser so requires, the Purchaser shall continue to invoice any customers in respect of contracts current at Completion.
- 2.2.2. The Vendor shall forthwith upon the execution hereof notify the interest of the Purchaser to the insurers of the Trading Assets and the EDT Business and keep in force its existing insurance policies in respect of the Trading Assets until 180 days after Completion.

- 2.3. **The Consideration:**

The consideration for the said sale shall be satisfied by the issue of the Loan Note in the name of the Vendor.

- 2.4. **Purchase of all the Trading Assets:** The Purchaser will not be obliged to complete the purchase of

any of the Trading Assets unless the purchase of all of the Trading Assets is completed simultaneously.

2.5. Value Added Tax (VAT):

- 2.5.1. The parties shall use their best endeavours to ensure that by virtue of the provisions of sections 20(2)(c) and 26(2) of the Value-Added Tax Consolidation Act 2010 no VAT will be chargeable in respect of the sale and purchase of the Trading Assets hereby agreed to be made.
- 2.5.2. Notwithstanding Clause 2.5.1, the Purchaser shall not be liable to pay to the Vendor or to any other person any amount representing VAT in respect of the sale of the Trading Assets unless the Vendor demonstrates to the satisfaction of the Purchaser that the provisions of sections 20(2)(c) and 26(2) of the Value-Added Tax Consolidation Act 2010 do not apply. For the avoidance of doubt, written confirmation from the Irish Revenue Commissioners on this point shall be treated as demonstration to the satisfaction of the Purchaser.
- 2.5.3. Subject to Clause 2.5.2, if VAT is properly chargeable in respect of the sale of the Trading Assets and the Vendor is accountable in respect of the payment of the VAT to the VAT authorities, the Vendor shall deliver to the Purchaser a VAT invoice prepared in a format which is in accordance with relevant VAT legislation. On receipt of this VAT invoice the Purchaser shall pay to the Vendor the amount of VAT properly arising in respect of the sale of the Trading Assets.
- 2.5.4. Notwithstanding Clause 2.5.2, if following the payment of any amount of VAT by the Purchaser to the Vendor in respect of the sale of the Trading Assets it is established that VAT was incorrectly chargeable, the Vendor shall pay to the Purchaser the amount of any VAT incorrectly charged. For the avoidance of doubt, only written confirmation from the Irish Revenue Commissioners shall be treated as establishing that VAT was incorrectly chargeable.
- 2.5.5. In the event that the Vendor will incur a clawback of VAT in relation to or arising from the sale, the parties hereby exercise a joint option to tax within the meaning of section 94(5) Value-Added Tax Consolidation Act 2010.

3. COMPLETION AND CONDITIONS

- 3.1. **Completion:** Subject to clause 3.2, Completion shall take place on the Effective Date at such address as the parties may agree.
- 3.2. **Closing Conditions:** Completion of this Agreement will take place conditionally upon:
 - 3.2.1. the simultaneous completion of the Business Transfer Agreement; and
 - 3.2.2. the Vendor having complied with its obligations under clause 5.
- 3.3. **Actions at Completion:** Upon Completion:
 - 3.3.1. possession of the Trading Assets shall, as far as practical, be delivered to the Purchaser;
 - 3.3.2. the Vendor shall procure that all other necessary parties (if any) execute and deliver to the Purchaser all such assurances and things as may be necessary to vest in the Purchaser good and marketable title to the Trading Assets (including deeds of assignment in relation to the Intellectual Property) including such evidence of corporate power and proper execution as the Purchaser may reasonably require;
 - 3.3.3. the Vendor and the Purchaser shall execute and deliver the Termination Letter;
 - 3.3.4. the Vendor and the Purchaser shall execute and deliver the Licence User Agreement;
 - 3.3.5. the Vendor and the Purchaser shall comply with the terms of clause 5 (in relation to the Employees); and
 - 3.3.6. the Vendor shall cause to be delivered to the Purchaser a tax clearance certificate pursuant to section 980 of the Taxes Consolidation Act 1997 (as amended) (**CGT Clearance Certificate**)

confirming that the Purchaser does not have to deduct any sum representing capital gains tax on payment of the consideration to the Vendor.

- 3.4. **Payments at Completion:** The Purchaser shall on Completion issue the Loan Note in the name of the Vendor less withholding tax if the CGT Clearance Certificate is not produced by the Vendor stating that tax should not be deducted from the consideration.

4. BUSINESS CONTRACTS

- 4.1. At Completion the Vendor will, at the option of the Purchaser, in respect of each Business Contract:-

- 4.1.1. assign (or procure the assignment of) the Business Contract in question to the Purchaser or its nominee(s); or
- 4.1.2. procure the novation of the Business Contract in question so that the Purchaser or its nominee(s) will become party to the relevant Business Contract in place of the Vendor

in each case on such terms as may be agreed to by the Purchaser.

- 4.2. Insofar as the consent of a third party is required to comply with the terms of clause 4.1, the Vendor shall use its best endeavours to procure such consent at its own cost and expense. Until such consent is received, the Vendor shall, following Completion, at the Purchaser's option either:-

- 4.2.1. unless contractually prevented from so doing, sub-contract the relevant Business Contract to the Purchaser on the same terms and for the same remuneration that applies to that Business Contract; or
- 4.2.2. act in connection with the Business Contract in all respects as the Purchaser may reasonably direct from time to time

so that (without prejudice to generality of the foregoing) the Purchaser will perform the obligations and liabilities arising under the Business Contract in question insofar as any such obligation or liability arises after Completion (provided that no such obligation or liability is in respect of any breach of the relevant Business Contract by the Vendor prior to Completion) and the full benefit of all contractual rights, benefits and claims thereunder whether arising before or after Completion shall vest in and be held on trust by the Vendor for the Purchaser absolutely.

- 4.3. To the extent that the Vendor is not lawfully able to hold the Business Contract in question on trust for the Purchaser, the parties shall make such other arrangements between themselves as the Purchaser may reasonably require to provide that (i) the benefit of the Business Contracts in question is received by the Purchaser, including the enforcement of all rights of the Vendor thereunder and (ii) the Purchaser will be responsible for carrying out the Vendor's obligations under such Business Contracts as set out above from Completion.
- 4.4. If any Business Contract is being novated then this Agreement does not act as a contract or agreement for the sale of any estate or interest in the Business Contracts nor does it operate to assign any of the Business Contracts. Instead the benefit of the Business Contracts will be novated to the Purchaser pursuant to the deed of novation which is to be entered into between the parties.

5. EMPLOYEES

- 5.1. **Safeguarding of Employees' Rights:** The Vendor shall discharge all of its obligations (if any) in relation to the Employees arising under or by virtue of the European Communities (Protection of Employees on Transfer of Undertakings) Regulations, 2003.
- 5.2. **Evidence and Information:** The Vendor shall both before and after Completion furnish to the Purchaser such evidence and information as the Purchaser may from time to time require in relation to the discharge by the Vendor of the Vendor's said obligations together with such other information as the Purchaser may from time to time require in relation to the intentions, proposals, obligations and actions of the Vendor in connection with contracts of employment, employment relationships or collective agreements and any other matters in connection therewith relating to any of the Employees.
- 5.3. **Other Obligations:** The Vendor shall perform and shall be fully liable and responsible for all obligations

and liabilities whatsoever pertaining to matters arising prior to Completion arising by virtue of or in connection with contracts of employment, employment relationships and/or collective agreements in existence at any time prior to Completion (whether discovered before or after Completion) including under any applicable statute and the Vendor hereby fully and effectually indemnifies and agrees to keep the Purchaser fully and effectually indemnified against all judgments, claims, decrees, prosecutions, orders, awards, damages, costs, liabilities and expenses howsoever arising (including costs, payments and expenses of any reasonable settlement entered into by the Purchaser with the prior consent of the Vendor, such consent not to be unreasonably withheld, delayed or conditioned) under or by virtue thereof. In the event that any claim, arising from circumstances prior to Completion, is made against the Purchaser, the Vendor shall furnish to the Purchaser such evidence and information as the Purchaser may require to defend those claims.

5.4. **Transfer of Employees:** The Vendor shall prior to Completion comply where appropriate with sections 9(2) and 20 of the Redundancy Payments Act, 1967 and shall facilitate the Purchaser in this regard so that continuity, where appropriate, is maintained.

5.5. The Vendor and the Purchaser shall not prior to the Effective Time unless otherwise required by law or with the prior agreement of Alkermes, Inc.

5.5.1. increase or offer, promise or agree to increase the remuneration (howsoever defined but including salary and any variable and/or incentive arrangements) or the severance arrangements in respect of any of the Employees;

5.5.2. increase or make offers of employment so as to increase the number of the Employees; or

5.5.3. replace or offer to redeploy any of the Employees.

6. MISCELLANEOUS PROVISIONS

6.1. Confidentiality

6.1.1. The Vendor undertakes with the Purchaser that it shall preserve the confidentiality of, and not directly or indirectly reveal, report, publish, disclose, transfer or use for its own or any other purposes Confidential Information except:

- (1) in the circumstances set out in clause 6.1.2;
- (2) to the extent otherwise expressly permitted by this Agreement; or
- (3) with the prior written consent of the Purchaser.

6.1.2. The Vendor is permitted to disclose Confidential Information:

- (1) where the Confidential Information, before it is furnished to the relevant Vendor, is in the public domain;
- (2) where the Confidential Information, after it is furnished to the relevant Vendor, enters the public domain otherwise than as a result of: (i) a breach by the relevant Vendor of its obligations in this clause 6.1 or (ii) a breach by the person who disclosed that Confidential Information of a confidentiality obligation where the relevant Vendor is aware of such breach;
- (3) if and to the extent that a Vendor discloses Confidential Information to any person:
 - (a) in compliance with any requirement of law;
 - (b) in response to a requirement of any securities exchange, regulatory or governmental authority or court having jurisdiction over the relevant Vendor; or
 - (c) in order to obtain Tax or other clearances or consents from the Revenue Commissioners or other relevant taxing or regulatory authorities,

provided that any such information disclosable pursuant to paragraphs (a), (b) or (c) may be disclosed only to the extent specifically required by law.

6.1.3. The restrictions contained in this clause 6.1 will continue to apply after Completion and will apply in relation to the existence and provisions of this Agreement and information relating to the Purchaser regardless of whether or not Completion occurs.

6.2. Severability

All the terms and provisions of this Agreement are distinct and severable, and if any term or provision is held or declared to be unenforceable, illegal or void in whole or in part by any court, regulatory authority or other competent authority it will to that extent only be deemed not to form part of this Agreement, and the enforceability, legality and validity of the remainder of this Agreement will not in any event be affected. The parties shall then use all reasonable endeavours to agree a term or provision to replace the unenforceable, illegal or void term or provision which is legal and enforceable and which has an effect that is near as possible to the intended effect of the term or provision to be replaced.

6.3. Whole Agreement

This Agreement (together with any documents to be executed pursuant to the terms of this Agreement) supersedes all prior representations, arrangements, understandings and agreements, and sets out the entire, complete and exclusive agreement and understanding between the parties. The rights of the Purchaser under this Agreement are independent, cumulative and without prejudice to all other rights available to it whether as a matter of common law, statute, custom or otherwise.

6.4. Survival

The provisions of this Agreement which have not been performed at Completion will remain in full force and effect notwithstanding Completion.

6.5. Remedies Cumulative

The provisions of this Agreement and the rights and remedies of the parties are cumulative and are without prejudice and in addition to any rights or remedies which a party may have at law or in equity. The exercise by a party of any one right or remedy under this Agreement or at law or in equity will not (unless expressly otherwise provided in this Agreement or at law or in equity) operate so as to hinder or prevent the exercise by that party of any other right or remedy.

6.6. Waiver

Any liability to the Purchaser under this Agreement may be wholly or partially released, varied, compounded or compromised by the Purchaser in its absolute discretion as regards the Vendor or any other party without in any way prejudicing or affecting its rights against any other party under the same or a similar liability, whether joint and several or otherwise. A waiver by the Purchaser of any breach by any party of any of the terms, provisions or conditions of this Agreement, or the acquiescence of the Purchaser in any act (whether commission or omission) which but for such acquiescence would be a breach, will not constitute a general waiver of the term, provision or condition or of any subsequent act which is inconsistent with it.

6.7. Further Assurance

6.7.1. Without limiting the generality of the foregoing, to the extent that the Purchaser or the Vendor discover following Completion that:

6.7.2. any Trading Asset that was intended to be assigned and transferred pursuant to this Agreement was not assigned and transferred at Completion, the Vendor shall (and shall procure that any other necessary parties shall) execute and do all such documents, acts and things as may reasonably be required to assign and transfer to the Purchaser the legal and beneficial ownership in such Trading Asset; and/or

6.7.3. any asset that was not a Trading Asset intended to be transferred pursuant to this Agreement was assigned and transferred at Completion, the Purchaser shall (and shall procure that any other parties shall) execute and do all such documents, acts and things as may reasonably be

required to assign and transfer to the Vendor the legal and beneficial ownership in such asset.

6.8. Notices

Any notice or other communication to be given or served under this Agreement shall be in writing, addressed to the relevant party and expressed to be a notice or communication under this Agreement and, without prejudice to the validity of another method of service, may be delivered or sent by pre-paid post or facsimile addressed to the recipient at the address given above or to its fax number at that address.

6.9. Counterparts

This Agreement may be executed in any number of counterparts, and by the several parties to it on separate counterparts, each of which when so executed will constitute an original but all of which together will evidence the same agreement.

6.10. Governing Law and Jurisdiction

This Agreement and all relationships created by it will in all respects be governed by and construed in accordance with Irish law. The Irish courts will have exclusive jurisdiction to settle any dispute which may arise out of or in connection with this Agreement or its performance.

6.11. Succession and Assignment

This Agreement will be binding upon and enure for the benefit of the permitted assigns and, where applicable, successors in title, administrators, executors and personal representatives of the parties. The benefit of any provision of this Agreement may be enforced by the beneficial owners for the time being of the EDT Business or any of the Trading Assets, and accordingly the benefit of any provision in this Agreement may be assigned at any time and from time to time by the Purchaser and its successors in title without the consent of the Vendor.

6.12. Variations

This Agreement may not be released, varied, discharged, amended or supplemented, except by an instrument in writing executed by each party or a duly authorised representative of each party.

6.13. Financial Transfers

The Vendor declares for the purpose of the Financial Transfers Act, 1992 that it is not resident in any jurisdiction to which financial transfers (within the meaning of that Act) are restricted by order of the Minister for Finance in accordance with the provisions of that Act and does not hold any of the Trading Assets, and will not receive any part of the consideration, as nominee for any persons so resident, and the Purchaser declares for the purpose of that Act that it is not so resident, is not acquiring the Trading Assets as nominee for any persons so resident and that the Purchaser is not to its knowledge controlled directly or indirectly by persons so resident.

6.13.1. Recitals


The parties acknowledge that matters referred to in the recitals will not, in any way, give rise to any liability or cause of action against the Purchaser.

IN WITNESS whereof this Agreement has been entered into on the date and year first herein written.

SIGNED for and on behalf of
ELAN PHARMA INTERNATIONAL LIMITED


.....
Director

SIGNED for and on behalf of
EDT PHARMA HOLDINGS LIMITED


.....
Director

SCHEDULE 1

Excluded Assets

For the avoidance of doubt, the Excluded Assets of the Vendor means:

- (1) all those assets and records of the Vendor which do not form part of the EDT Business
- (2) all cash and bank accounts of the Vendor;
- (3) the Manufacturing Business; and
- (4) the statutory books of the Vendor.

SCHEDULE 2

Patents

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0002.US		ORD	USA	5260478	07/986,646		08-Dec-1992	08-Dec-2012	IODINATED AROYLOXY CARBOXAMIDES
01.0003.US		ORD	USA	5264610	08/038,371		29-Mar-1993	29-Mar-2013	IODINATED AROMATIC PROPANEDIOATES
01.0003.US	2	DIV	USA	5328404	08/148,112		04-Nov-1993	29-Mar-2013	METHOD OF X-RAY IMAGING USING IODINATED AROMATIC PROPANEDIOATES
01.0004.US		ORD	USA	5298262	07/987,904		04-Dec-1992	04-Dec-2012	USE OF IONIC CLOUD POINT MODIFIERS TO PREVENT PARTICLE AGGREGATION DURING STERILIZATION
01.0005.US		ORD	USA	5302401	07/987,879		09-Dec-1992	09-Dec-2012	METHOD TO REDUCE PARTICLE SIZE GROWTH DURING LYOPHILIZATION
01.0006.US	3	DIV	USA	5451393	08/207,533		07-Mar-1994	19-Sep-2012	X-RAY CONTRAST COMPOSITIONS USEFUL IN MEDICAL IMAGING
01.0007.US		ORD	USA	5322679	07/990,987		16-Dec-1992	16-Dec-2012	IODINATED AROYLOXY ESTERS
01.0007.US	2	CIP	USA	5466433	08/261,794		20-Jun-1994	16-Dec-2012	IODINATED AROYLOXY ESTERS
01.0008.US		ORD	USA	5326552	07/991,909		17-Dec-1992	17-Dec-2012	FORMULATIONS FOR NANOPARTICULATE X-RAY BLOOD POOL CONTRAST AGENTS USING HIGH MOLECULAR WEIGHT NONIONIC SURFACTANTS
01.0008.US	2	DIV	USA	5447710	08/242,492		13-May-1994	05-Sep-2012	METHOD OF MAKING NANOPARTICULATE X-RAY BLOOD POOL CONTRAST AGENTS USING HIGH MOLECULAR WEIGHT NONIONIC SURFACTANTS
01.0009.US		ORD	USA	5330739	07/985,415		04-Dec-1992	04-Dec-2012	IODINATED BENZOYL ACETALS AND KETALS FOR X-RAY IMAGING
01.0010.US	2	DIV	USA	5470583	08/240,309		10-May-1994	11-Dec-2012	METHOD OF PREPARING NANOPARTICLE COMPOSITIONS CONTAINING CHARGED PHOSPHOLIPIDS TO REDUCE AGGREGATION
01.0012.US			USA	5346688	07/991,640			16-Dec-2012	IODINATED WETTING AGENTS
01.0013.US		ORD	USA	5346702	07/985,424		04-Dec-1992	04-Dec-2012	USE OF NON-IONIC CLOUD POINT MODIFIERS TO MINIMIZE NANOPARTICLE AGGREGATION DURING STERILIZATION
01.0015.US		ORD	USA	5352459	07/991,639		16-Dec-1992	16-Dec-2012	USE OF PURIFIED SURFACE MODIFIERS TO PREVENT PARTICLE AGGREGATION DURING STERILIZATION
01.0016.US	2	CON	USA	5384107	08/285,595		03-Aug-1994	14-Dec-2012	IODINATED AROMATIC COMPOUNDS
01.0017.US	2	DIV	USA	5494683	08/365,267		28-Dec-1994	27-Feb-2013	SURFACE MODIFIED ANTICANCER NANOPARTICLES
01.0018.US		ORD	USA	5401492	07/991,893		17-Dec-1992	17-Dec-2012	WATER INSOLUBLE NON-MAGNETIC MANGANESE PARTICLES AS MAGNETIC RESONANCE CONTRAST ENHANCEMENT AGENTS
01.0019.US		ORD	USA	5429824	07/990,874		15-Dec-1992	15-Dec-2012	USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
01.0020.US		ORD	USA	5466440	08/367,407		30-Dec-1994	30-Dec-2014	FORMULATIONS OF ORAL GASTROINTESTINAL DIAGNOSTIC X-RAY CONTRAST AGENTS IN COMBINATION WITH PHARMACEUTICALLY ACCEPTABLE CLAYS
01.0021.US	2	CON	USA	5643552	08/524,145		22-Aug-1995	22-Aug-2015	NANOPARTICULATE DIAGNOSTIC MIXED CARBONIC ANHYDRIDES AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0021.US	3	ORD	USA	5472683	08/401,570		09-Mar-1995	09-Mar-2015	NANOPARTICULATE DIAGNOSTIC MIXED CARBAMIC ANHYDRIDES AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
01.0021.US	4	ORD	USA	5573749	08/401,397		09-Mar-1995	09-Mar-2015	NANOPARTICULATE DIAGNOSTIC MIXED CARBOXYLIC ANHYDRIDES AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
01.0022.US		ORD	USA	5488133	08/209,181		10-Mar-1994	10-Mar-2014	IODINATED AROYLOXY KETONES
01.0023.US		ORD	USA	5500204	08/386,788		10-Feb-1995	10-Feb-2015	NANOPARTICULATE DIAGNOSTIC DIMERS AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
01.0024.US		ORD	USA	5503723	08/385,531		08-Feb-1995	08-Feb-2015	ISOLATION OF ULTRA SMALL PARTICLES
01.0025.US		ORD	USA	5510118	08/388,092		14-Feb-1995	14-Feb-2015	PROCESS OF PREPARING THERAPEUTIC COMPOSITIONS CONTAINING NANOPARTICLES
01.0026.US	2	CON	USA	5518187	08/180,827		12-Jan-1994	12-Jan-2014	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
01.0027.US		ORD	USA	5518738	08/385,614		09-Feb-1995	09-Feb-2015	NANOPARTICULATE NSAID COMPOSITIONS
01.0028.US		ORD	USA	5521218	08/440,794		15-May-1995	15-May-2015	NANOPARTICULATE IODIPAMIDE DERIVATIVES FOR USE AS X-RAY CONTRAST AGENTS
01.0029.US		ORD	USA	5525328	08/265,550		24-Jun-1994	24-Jun-2014	NANOPARTICULATE DIAGNOSTIC DIATRIZOXY ESTER X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
01.0030.US		ORD	USA	5534270	08/386,028		09-Feb-1995	09-Feb-2015	METHOD OF PREPARING STABLE DRUG NANOPARTICLES
01.0031.US		ORD	USA	5543133	08/388,099		14-Feb-1995	14-Feb-2015	PROCESS OF PREPARING X-RAY CONTRAST COMPOSITIONS CONTAINING NANOPARTICLES
01.0033.US		ORD	USA	5571536	08/384,057		06-Feb-1995	06-Feb-2015	FORMULATIONS OF COMPOUNDS AS NANOPARTICULATE DISPERSIONS IN DIGESTIBLE OILS OR FATTY ACIDS
01.0033.US	2	ORD	USA	5560931	08/388,088		14-Feb-1995	14-Feb-2015	FORMULATIONS OF COMPOUNDS AS NANOPARTICULATE DISPERSIONS IN DIGESTIBLE OILS OR FATTY ACIDS
01.0034.US		ORD	USA	5560932	08/370,955		10-Jan-1995	10-Jan-2015	MICROPRECIPITATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS
01.0035.US		ORD	USA	5565188	08/393,972		24-Feb-1995	24-Feb-2015	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES
01.0035.US	2	CIP	USA	5705194	08/727,863		08-Oct-1996	24-Feb-2015	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANO PARTICLES
01.0036.US		ORD	USA	5569448	08/378,022		24-Jan-1995	24-Jan-2015	SULFATED NONIONIC BLOCK COPOLYMER SURFACTANTS AS STABILIZER COATINGS FOR NANOPARTICLE COMPOSITIONS
01.0037.US		ORD	USA	5573750	08/447,133		22-May-1995	22-May-2015	DIAGNOSTIC IMAGING X-RAY CONTRAST AGENTS
01.0038.US		ORD	USA	5573783	08/387,651		13-Feb-1995	13-Feb-2015	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS

PATENT

REEL: 029043 FRAME: 0497

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0039.US		ORD	USA	5580579	08/388,878		15-Feb-1995	15-Feb-2015	SITE-SPECIFIC ADHESION WITHIN THE GI TRACT USING NANOPARTICLES STABILIZED BY HIGH MOLECULAR WEIGHT, LINEAR POLY (ETHYLENE OXIDE) POLYMERS
01.0040.US		ORD	USA	5585108	08/366,518		30-Dec-1994	30-Dec-2014	FORMULATIONS OF ORAL GASTROINTESTINAL THERAPEUTIC AGENTS IN COMBINATION WITH PHARMACEUTICALLY ACCEPTABLE CLAYS
01.0041.US		ORD	USA	5587143	08/267,082		28-Jun-1994	28-Jun-2014	BUTYLENE OXIDE-ETHYLENE OXIDE BLOCK COPOLYMER NANOPARTICLE COMPOSITIONS
01.0042.US		ORD	USA	5591456	08/386,790		10-Feb-1995	10-Feb-2015	MILLED NAPROXEN WITH HYDROXYPROPYL CELLULOSE AS A DISPERSION STABILIZER
01.0043.US		ORD	USA	5593657	08/386,027		09-Feb-1995	09-Feb-2015	NOVEL BARIUM SALT FORMULATIONS STABILIZED BY NON-IONIC AND ANIONIC STABILIZERS
01.0044.US		ORD	USA	5603916	08/447,132		22-May-1995	22-May-2015	3 5-BIS ALKANOYL AMINO-2 4 6-TRIODOBENZYL ESTERS
01.0045.US	2	CIP	USA	5622938	08/444,796		19-May-1995	09-Feb-2015	SUGAR BASE SURFACTANT FOR NANOCRYSTALS FORMULATIONS OF ORAL GASTROINTESTINAL
01.0046.US		ORD	USA	5628981	08/366,841		30-Dec-1994	30-Dec-2014	DIAGNOSTIC X-RAY CONTRAST AGENTS AND ORAL GASTROINTESTINAL THERAPEUTIC AGENTS
01.0046.US	2	CIP	USA	6432381	08/815,346	US 2001-0006617 A1	11-Mar-1997	30-Dec-2014	METHODS FOR TARGETING DRUG DELIVERY TO THE UPPER AND/OR LOWER GASTROINTESTINAL TRACT
01.0046.US	3	CON	USA		10/175,851	US 2003-0054045 A1	21-Jun-2002	30-Dec-2014	METHODS FOR TARGETING DRUG DELIVERY TO THE UPPER AND/OR LOWER GASTROINTESTINAL TRACT
01.0047.US		ORD	USA	5662883	08/370,936		10-Jan-1995	10-Jan-2015	MICROPRECIPIATION OF MICRO-NANOPARTICULATE PHARMACEUTICAL AGENTS
01.0049.US		ORD	USA	5665331	08/370,998		10-Jan-1995	10-Jan-2015	CO-MICROPRECIPIATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS WITH CRYSTAL GROWTH MODIFIERS
01.0050.US		ORD	USA	5668196	08/677,709		10-Jul-1996	10-Jul-2016	NOVEL 3-AMIDO-TRIODOPHENYL ESTERS AS X-RAY CONTRAST AGENTS
01.0051.US		CON	USA	5670136	08/586,363		16-Jan-1996	23-Sep-2014	2,4,6-TRIIDO-5-SUBSTITUTED-AMINO-ISOPHTHALATE ESTERS USEFUL AS X-RAY CONTRAST AGENTS FOR MEDICAL DIAGNOSTICS IMAGING
01.0052.US		ORD	USA	5716642	08/370,928		10-Jan-1995	10-Feb-2015	MICROPRECIPIATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS USING SURFACE ACTIVE MATERIAL DERIVED FROM SIMILAR PHARMAC
01.0053.US		ORD	USA	5718388	08/249,787		25-May-1994	17-Feb-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
01.0054.US		ORD	USA	5718919	08/393,648		25-May-1994	17-Feb-2015	NANOPARTICLES CONTAINING THE R(-)ENANTIOMER OF IBUPROFEN
01.0055.US		ORD	USA	5747001	08/393,973		24-Feb-1995	05-May-2015	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICLE DISPERSIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0056.US	2	ORD	USA	5834025	08/696,754		14-Aug-1996	14-Aug-2016	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
01.0056.US	3	REI	USA	RE41,884 E	12/027,100		06-Feb-2008	14-Aug-2016	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
01.0057.US	2	CON	USA	5862999	08/491,539		15-Jun-1995	25-May-2014	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
01.0058.US		ORD	USA	5936030	08/836,819		14-Aug-1997	10-Aug-2016	POLYETHER COPOLYMERS AND A PROCESS FOR PREPARING THEM
01.0059.US	2	CIP	USA	6045829	08/890,602		09-Jul-1997	13-Feb-2017	NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS
01.0059.US	3	DIV	USA	6068858	09/225,493		06-Jan-1999	09-Jul-2017	METHODS OF MAKING NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS
01.0059.US	4	CIP	USA	6221400	09/225,498		06-Jan-1999	13-Feb-2017	METHODS OF TREATING MAMMALS USING NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS
01.0060.US		ORD	USA	6153225	09/154,422		13-Aug-1998	13-Aug-2018	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
01.0061.US		ORD	USA	6165506	09/148,332		04-Sep-1998	04-Sep-2018	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN
01.0062.US		CON	USA	6264922	08/948,216		09-Oct-1997	24-Feb-2015	NEBULIZED AEROSOLS CONTAINING NANOPARTICULATE DISPERSIONS
01.0062.US	2	DIV	USA		09/577,489		22-May-2000	24-Feb-2015	METHODS OF ADMINISTERING LIQUID DROPLET AEROSOLS OF NANOPARTICULATE DRUGS
01.0062.US	3	CON	USA		12/081,670	US 2008-0274044 A1	18-Apr-2008	24-Feb-2015	METHODS OF ADMINISTERING LIQUID DROPLET AEROSOLS OF NANOPARTICULATE DRUGS
01.0063.US		ORD	USA	7,521,068 B2	09/190,138	US 2002-0102294 A1	12-Nov-1998	12-Apr-2022	DRY POWDER AEROSOLS OF NANOPARTICULATE DRUGS
01.0063.US	2	DIV	USA	6811767	09/597,738		19-Jun-2000	12-Nov-2018	LIQUID DROPLET AEROSOLS OF NANOPARTICULATE DRUGS
01.0063.US	3	CON	USA		12/320,431	US 2009-0181100 A1	26-Jan-2009	12-Nov-2018	LIQUID DROPLET AEROSOLS OF NANOPARTICULATE DRUGS
01.0064.US		ORD	USA	6270806	09/261,151		03-Mar-1999	03-Mar-2019	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
01.0065.US		ORD	USA	6267989	09/263,834		08-Mar-1999	08-Mar-2019	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0066.US		ORD	USA	6656504	09/392,557		09-Sep-1999	09-Sep-2019	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOPROLINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
01.0067.US	2	CIP	USA		09/337,675	US 2002-0012675 A1	22-Jun-1999	01-Oct-2018	CONTROLLED-RELEASE NANOPARTICULATE COMPOSITIONS
01.0067.US	4	CON	USA		11/979,231	US 2008-0124393 A1	31-Oct-2007	01-Oct-2018	CONTROLLED-RELEASE NANOPARTICULATE CLOZAPINE COMPOSITIONS
01.0067.US	6	CON	USA		12/483,188	US 2009-0297619 A1	11-Jun-2009	22-Jun-2019	NANOPARTICULATE ANTICONVULSANT AND IMMUNOSUPPRESSIVE COMPOSITIONS
01.0067.US		CON	USA		13/102,795		06-May-2001	01-Oct-2018	CONTROLLED-RELEASE NANOPARTICULATE CLOZAPINE COMPOSITIONS
01.0068.US		ORD	USA	6428814	09/414,159	US 2002-0068092 A1	08-Oct-1999	08-Oct-2019	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
01.0068.US	2	DIV	USA	7288267	10/004,808	US 2003-0108611 A1	08-Oct-1999	23-May-2021	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
01.0068.US	3	DIV	USA	7850995	11/898,274	US 2008 0003295 A1	11-Sep-2007	08-Oct-2019	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
01.0069.US	2	ORD	USA	6431478	09/583,893		31-May-2000	26-Jul-2020	SMALL-SCALE MILL AND METHOD THEREOF
01.0069.US	3	DIV	USA	6745962	10/037,566	US 2002-0145062 A1	19-Oct-2001	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
01.0069.US	4	CON	USA	6991191	10/833,045	US 2004-0251332 A1	28-Apr-2004	30-Jun-2020	SMALL-SCALE MILL AND METHOD THEREOF
01.0070.US		ORD	USA	6316029	09/572,961		18-May-2000	18-May-2020	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
01.0070.US	2	CON	USA		10/667,470	US 2004-0057993 A1	23-Sep-2003	18-May-2020	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
01.0070.US	4	CON	USA		12/068,706	US 2008-0213371 A1	11-Feb-2008	18-May-2020	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
01.0071.US		ORD	USA	6375986	09/666,539		21-Sep-2000	21-Sep-2020	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
01.0071.US	2	CON	USA	6592903	10/075,443	US 2002-0110597 A1	15-Feb-2002	21-Sep-2020	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
01.0072.US	2	CIP	USA	6969529	10/345,312	US 2003-0108616 A1	16-Jan-2003	21-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABILIZERS
01.0072.US	3	DIV	USA	7244451	11/213,765	US 2007-0141159 A1	30-Aug-2005	05-Feb-2021	METHODS OF MAKING NANOPARTICULATE DRUG COMPOSITIONS COMPRISING COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABILIZERS
01.0077.US	2	ORD	USA	6582285	09/842,619	US 2001-0053664 A1	26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0078.US	2	ORD	USA		10/246,751	US 2003-0095928 A1	19-Sep-2002	19-Sep-2022	NANOPARTICULATE COMPOSITIONS OF INSULIN
01.0079.US	2	ORD	USA	6742734	10/162,333	US 2002-0179758 A1	04-Jun-2002	06-Aug-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
01.0079.US	3	CIP	USA	6976647	10/732,801	US 2004-0164194 A1	11-Dec-2003	04-Jun-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
01.0079.US	5	DIV	USA	7575184	11/833,645	US 2008-0025807 A1	03-Aug-2007	04-Aug-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
01.0080.US		ORD	USA		09/952,032	US 2003-0054042 A1	14-Sep-2001	14-Sep-2021	STABILIZATION OF CHEMICAL COMPOUNDS USING NANOPARTICULATE FORMULATIONS
01.0080.US	3	CON	USA		11/802,158	US 2007-0224279 A1	21-May-2007	14-Sep-2021	STABILIZATION OF CHEMICAL COMPOUNDS USING NANOPARTICULATE FORMULATIONS
01.0080.US	4	CON	USA		11/979,251		31-Oct-2007	14-Sep-2021	STABILIZATION OF CHEMICAL COMPOUNDS USING NANOPARTICULATE FORMULATIONS
01.0080.US	5	CON	USA		12/121,443	US 2009-0175951 A1	15-May-2008	14-Sep-2021	IMMUNOSUPPRESSIVE AGENTS
01.0083.US	2	ORD	USA	7459283	10/357,514	US 2003-0185869 A1	04-Feb-2003	10-Jul-2026	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
01.0083.US	3	CON	USA		12/292,091	US 2009-0074875 A1	12-Nov-2008	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
01.0086.US	3	CIP	USA		11/275,069	US 2006-0193920 A1	07-Dec-2005	21-Sep-2020	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
01.0088.US		ORD	USA		10/035,324	US 2003-0129242 A1	04-Jan-2002	04-Jan-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
01.0089.US	2	ORD	USA	7713551	10/659,706	US 2005-0031691 A1	11-Sep-2003	12-Nov-2024	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
01.0091.US	4	DIV	USA		11/928,250	US 2008-0050461 A1	30-Oct-2007	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	5	DIV	USA		11/928,278	US 2008-0107741 A1	30-Oct-2007	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	6	DIV	USA		11/928,289	US 2008-0226732 A1	30-Oct-2007	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	7	CIP	USA		12/076,247	US 2008-0220075 A1	14-Mar-2008	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	8	CON	USA		12/117,982	US 2008-0279949 A1	09-May-2008	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	9	CON	USA		12/870,722	US 2010-0322852 A1	27-Aug-2010	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	10	CON	USA		12/870,745	US 2010-0322853 A1	27-Aug-2010	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
01.0091.US	11	CON	USA		12/870,749	US 2010-0329976 A1	27-Aug-2010	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0092.US	3	ORD	USA	 7101576	10/412,669	US 2003-0219490 A1	14-Apr-2003	12-Apr-2024	NANOPARTICULATE MEGESTROL FORMULATIONS
01.0092.US	4	CIP	USA		10/878,623	US 2005-0008707 A1	29-Jun-2004	14-Apr-2023	NANOPARTICULATE MEGESTROL FORMULATIONS
01.0092.US	5	CIP	USA		11/093,149	US 2005-0233001 A1	30-Mar-2005	14-Apr-2023	NANOPARTICULATE MEGESTROL FORMULATIONS
01.0092.US	6	CIP	USA		11/472,556	US 2010-0226989 A1	22-Jun-2006		NANOPARTICULATE MEGESTROL FORMULATIONS
01.0092.US	8	CON	USA		12/826,557	US 2010-0266705 A1	29-Jun-2010	14-Apr-2023	NANOPARTICULATE MEGESTROL FORMULATIONS
01.0093.US	3	CIP	USA	 7276249	10/444,066	US 2005-0276974 A1	23-May-2003	21-Feb-2023	NANOPARTICULATE FIBRATE FORMULATIONS
01.0093.US	4	DIV	USA	 7320802	10/692,855	US 2004-0058009 A1	27-Oct-2003	21-Feb-2023	METHODS OF TREATMENT USING NANOPARTICULATE FENOFIBRATE COMPOSITIONS
01.0093.US	11	CIP	USA		11/710,607	US 2007-0264348 A1	26-Feb-2007	21-Feb-2023	NANOPARTICULATE FIBRATE FORMULATIONS
01.0093.US	12	CON	USA		11/802,542	US 2007-0298115 A1	23-May-2007	21-Feb-2023	NANOPARTICULATE FIBRATE FORMULATIONS
01.0093.US	13	CON	USA		11/802,567	US 2008-0095851 A1	23-May-2007	21-Feb-2023	NANOPARTICULATE FIBRATE FORMULATIONS
01.0093.US	15	CON	USA		11/979,230	US 2008-0138424 A1	31-Oct-2007	21-Feb-2023	NANOPARTICULATE FIBRATE FORMULATIONS
01.0093.US	16	CIP	USA		12/058,497	US 2008-0241070 A1	28-Mar-2008	21-Feb-2023	NANOPARTICULATE FIBRATE FORMULATIONS
01.0096.US	4	CON	USA		11/367,716	US 2011-0027371 A1	06-Mar-2006	01-Oct-2018	NANOPARTICULATE STATIN FORMULATIONS & NOVEL STATIN COMBINATIONS
01.0098.US	2	ORD	USA	7,763,278 B2	10/457,811	US 2003-0232796 A1	10-Jun-2003	03-Mar-2024	NANOPARTICULATE POLYCOSANOL FORMULATIONS AND NOVEL POLYCOSANOL COMBINATIONS
01.0098.US	3	DIV	USA		12/704,426	US 2010-0143962 A1	11-Feb-2010	10-Jun-2023	NANOPARTICULATE POLYCOSANOL FORMULATIONS AND NOVEL POLYCOSANOL COMBINATIONS
01.0099.US	2	ORD	USA		10/784,900	US 2004-0229038 A1	24-Feb-2004	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
01.0099.US	3	CIP	USA		12/788,203	US 2010-0297252 A1	26-May-2010	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
01.0100.US	2	ORD	USA		10/705,227	US 2004-0156895 A1	12-Nov-2003	12-Nov-2023	SOLID DOSAGE FORMS COMPRISING PULLULAN
01.0102.US	2	ORD	USA		10/619,539	US 2004-0258757 A1	16-Jul-2003	16-Jul-2023	LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
01.0102.US	3	DIV	USA		13/044,450		09-Mar-2011		LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
01.0103.US	2	ORD	USA		10/654,600	US 2004-0105778 A1	04-Sep-2003	04-Sep-2023	GAMMA IRRADIATION OF SOLID NANOPARTICULATE ACTIVE AGENTS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0105.US		CIP	USA	7,198,795 B2	10/323,736	US 2004-0029099 A1	20-Dec-2002	07-Jan-2021	IN VITRO METHODS FOR EVALUATING THE IN VIVO EFFECTIVENESS OF DOSAGE FORMS OF MICROPARTICULATE OR NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
01.0105.US	2	CON	USA	7695739	11/650,412		08-Jan-2007	21-Sep-2020	IN VITRO METHODS FOR EVALUATING THE IN VIVO EFFECTIVENESS OF DOSAGE FORMS OF MICROPARTICULATE OR NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
01.0105.US	3	CON	USA		12/729,018	US 2010-0178648-A1	22-Mar-2010	21-Sep-2020	IN VITRO METHODS FOR EVALUATING THE IN VIVO EFFECTIVENESS OF DOSAGE FORMS OF MICROPARTICULATE OR NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
01.0106.US	4	ORD	USA	7390505	10/766,960	US 2004-0258758 A1	30-Jan-2004	30-Jan-2024	NANOPARTICULATE TOPIRAMATE FORMULATIONS
01.0107.US	2	ORD	USA		10/768,194	US 2004-0208833 A1	02-Feb-2004		NOVEL FLUTICASONE FORMULATIONS
01.0107.US		CON	USA		13/189,299		22-Jul-2001	02/02/2024	NOVEL FLUTICASONE FORMULATIONS
01.0108.US	2	CIP	USA		10/420,927	US 2004-0105889 A1	23-Apr-2003	14-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
01.0108.US	3	CON	USA		11/979,253	US 2008-0152585 A1	31-Oct-2007	14-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
01.0109.US	2	ORD	USA	7842232	10/851,661	US 2010-0255102 A1	24-May-2004	29-Jun-2027	STERILIZATION OF DISPERSIONS OF NANOPARTICULATE ACTIVE AGENTS WITH GAMMA RADIATION
01.0110.US	2	ORD	USA		10/895,405	US 2005-0042177 A1	21-Jul-2004		NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
01.0112.US		CIP	USA		10/697,703	US 2004-0156872 A1	31-Oct-2003		NOVEL NIMESULIDE COMPOSITIONS
01.0112.US		CON	USA		13/193,545		28-Jul-2011	18/05/2021	NOVEL NIMESULIDE COMPOSITIONS
01.0114.US	6	CON	USA		12/292,092	US 2009-0074873 A1	12-Nov-2008	24-Feb-2015	NANOPARTICULATE BECLOMETHASONE DIPROPIONATE COMPOSITIONS
01.0115.US		CIP	USA		10/697,716	US 2004-0141925 A1	31-Oct-2003	16-Jul-2023	NOVEL TRIAMCINOLONE COMPOSITIONS
01.0116.US		CIP	USA		10/701,064	US 2005-0019412 A1	05-Nov-2003		NOVEL GLIPIZIDE COMPOSITIONS
01.0117.US		CIP	USA		10/712,259	US 2004-0115134 A1	14-Nov-2003	22-Jun-2019	NOVEL NIFEDIPINE COMPOSITIONS
01.0117.US	2	CON	USA		11/980,720	US 2009-0047209 A1	31-Oct-2007	22-Jun-2019	NOVEL NIFEDIPINE COMPOSITIONS
01.0117.US	3	CON	USA		12/292,395	US 2009-0104273 A1	18-Nov-2008	22-Jun-2019	NOVEL NIFEDIPINE COMPOSITIONS
01.0119.US		CIP	USA		10/677,857	US 2004-0101566 A1	03-Oct-2003		NOVEL BENZOYL PEROXIDE COMPOSITIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0121.US	2	ORD	USA	7879360	10/978,695	US 2005-0238725 A1	02-Nov-2004	20-Feb-2028	NANOPARTICULATE COMPOSITIONS HAVING A PEPTIDE AS A SURFACE STABILIZER
01.0122.US	2	ORD	USA		10/979,792	US 2005-0147664 A1	03-Nov-2004	03-Nov-2024	COMPOSITIONS COMPRISING ANTIBODIES AND METHODS OF USING THE SAME FOR TARGETED NANOPARTICULATE ACTIVE AGENT DELIVERY
01.0123.US	2	ORD	USA	7910577	11/274,887	US 2006-0154918 A1	16-Nov-2005	26-Jan-2029	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
01.0123.US	3	CIP	USA		12/333,233		12-Nov-2008	16-Nov-2025	NANOPARTICULATE FORMULATIONS OF OLANZAPINE ESTERS
01.0123.US	4	DIV	USA		13/024,315		09-Feb-2011	16-Nov-2025	NANOPARTICULATE FORMULATIONS OF OLANZAPINE ESTERS
01.0124.US	3	CON	USA		12/232,895	US 2009-0035366 A1	25-Sep-2008		NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
01.0125.US	3	ORD	USA		11/633,088		04-Dec-2006	04-Dec-2026	NOVEL MOMETASONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
01.0132.US	2	ORD	USA		11/377,650	US 2006-0210639 A1	17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
01.0134.US	2	ORD	USA		11/376,554	US 2006-0210638 A1	16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
01.0135.US	2	ORD	USA		11/387,068	US 2006-0216353 A1	23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
01.0137.US	2	ORD	USA		11/402,264		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
01.0140.US	2	ORD	USA		11/402,257	US 2006-0246141 A1	12-Apr-2006	12-Apr-2026	NANOPARTICULATE LIPASE INHIBITOR FORMULATIONS
01.0143.US	2	ORD	USA		11/436,887		19-May-2006	19-May-2026	NANOPARTICULATE INTEGRIN ANTAGONIST FORMULATIONS
01.0143.US	3	CON	USA		11/980,719		31-Oct-2007	19-May-2026	NANOPARTICULATE INTEGRIN ANTAGONIST FORMULATIONS
01.0149.US	2	ORD	USA		11/437,833	US 2010-0028439-A1	22-May-2006	22-May-2026	NANOPARTICULATE STABILIZED ANTI-HYPERTENSIVE COMPOSITIONS
01.0151.US	2	CIP	USA		12/052,436	US 2008-0220074 A1	20-Mar-2008	04-Sep-2023	GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHOD OF MAKING SAME
01.0152.US		ORD	USA		11/363,266	US 2007-0202180 A1	28-Feb-2006	28-Feb-2026	NANOPARTICULATE CARVEDILOL FORMULATIONS
01.0153.US	2	ORD	USA		11/275,775	US 2007-0178051 A1	27-Jan-2006		STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
01.0154.US	5	CON	USA		12/071,849	US 2008-0152720 A1	27-Feb-2008	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
01.0154.US	6	CON	USA		12/484,073	US 2009-0252806 A1	12-Jun-2009	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
01.0155.US	4	DIV	USA		13/039,249		02-Mar-2011	21-Dec-2025	NANOPARTICULATE BICALUTAMIDE FORMULATIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
01.0156.US	2	ORD	USA		11/361,055	US 2006-0188566 A1	24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
01.0157.US	2	ORD	USA		11/354,249	US 2006-0198896 A1	15-Feb-2006		AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
01.0157.US	3	CON	USA		12/544,197	US 2009-0304801 A1	19-Aug-2009	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
01.0160.US	2	ORD	USA		11/325,626	US 2006-0165806 A1	05-Jan-2006		NANOPARTICULATE CANDESARTAN FORMULATIONS
01.0163.US	2	ORD	USA		11/372,227	US 2006-0204588 A1	10-Mar-2006	10-Mar-2026	FORMULATIONS OF A NANOPARTICULATE FINASTERIDE, DUTASTERIDE OR TAMSULOSIN HYDROCHLORIDE, AND MIXTURES THEREOF
01.0165.US	2	ORD	USA		11/446,589	US 2007-0042049 A1	05-Jun-2006	05-Jun-2026	NANOPARTICULATE BENIDIPINE COMPOSITIONS
01.0167.US	2	ORD	USA		11/446,564	US 2006-0292214 A1	05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN FORMULATIONS
01.0168.US	2	ORD	USA		11/446,565	US 2006-0275372 A1	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
01.0169.US	2	ORD	USA		11/448,984	US 2007-0059371 A1	08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
01.0172.US	3	ORD	USA		11/802,427		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
01.0174.US	2	ORD	USA		11/481,257		06-Jul-2006	06-Jul-2026	NANOPARTICULATE CLARITHROMYCIN FORMULATIONS
01.0176.US	2	ORD	USA		11/520,059	US 2007-0104792 A1	13-Sep-2006	13-Sep-2026	NANOPARTICULATE TADALAFIL FORMULATIONS
01.0177.US	2	ORD	USA		11/520,058	US 2007-0148100 A1	13-Sep-2006	13-Sep-2026	INJECTABLE FORMULATIONS OF NANOPARTICULATE ARIPIPRAZOLE
01.0178.US	1	ORD	USA		11/761,900		12-Jun-2007	12-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
01.0180.US	2	ORD	USA		11/775,002	US 2008-0213374 A1	09-Jul-2007	09-Jul-2027	NANOPARTICULATE FORMULATIONS OF SORAFENIB TOSYLATE
01.2004.US	2	ORD	USA		11/129,807		16-May-2005	16-May-2025	NANOPARTICLE DISPERSION CONTAINING LACTAM COMPOUND
01.2007.US	2	ORD	USA		12/331,052		09-Dec-2008	09-Dec-2028	NANOPARTICULATE ANIDULAFUNGIN COMPOSITIONS AND METHODS FOR MAKING THE SAME
01.2013.US		ORD	France		113500		26-May-2010	26-May-2030	NANOPARTICULATE ANTICANCER COMPOSITIONS AND METHODS FOR MAKING THE SAME
01.2021.US	3	ORD	USA		12/329,566	2009-0311335 A1	24-Feb-2009	24-Feb-2029	COMBINATION OF A TRIPTAN AND AN NSAID
01.2033.US		ORD	USA		13/110,647		18-May-2001	18-May-2031	NANOPARTICULATE CINACALCET COMPOSITIONS
02.1007.US		ORD	USA		11/262,672		31-Oct-2005	31-Oct-2025	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
02.1007.US	2	CIP	USA		11/373,629	US 2007-0098791 A1	10-Mar-2006	31-Oct-2025	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
02.1008.US	2	ORD	USA		11/569,483	US 2008-0268043 A1	01-Feb-2008	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
02.1009.US	2	ORD	USA		11/329,893	US 2006-0269596 A1	11-Jan-2006	11-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ACYLANILIDE
02.1011.US	2	ORD	USA		11/568,841		29-Jun-2007	14-Feb-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING LEVETIRACETAM
02.1012.US	2	ORD	USA		11/571,379		12-Apr-2006	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
02.1013.US	2	ORD	USA		11/558,202	US 2007-0122481 A1	09-Nov-2006	01-Nov-2019	MODIFIED RELEASE COMPOSITIONS COMPRISING A FLUOROCYTIDINE DERIVATIVE FOR THE TREATMENT OF CANCER
02.1103.US		CIP	USA		11/568,925		16-Nov-2006	01-Nov-2019	MODIFIED RELEASE LOXOPROFEN COMPOSITIONS
02.1107.US	2	PCT	USA		11/422,226	US 2008-0118556 A1	05-Jun-2006	01-Nov-2019	MODIFIED RELEASE OF COMPOSITIONS CONTAINING A COMBINATION OF CARBIDOPA, LEVODOPA AND ENTACAPONE
02.1200.US	4	CON	USA	5505962	08/307,392		16-Sep-1994	09-Apr-2013	CONTROLLED RELEASE PHARMACEUTICAL FORMULATION
02.1255.US		ORD	USA	5641745	08/479,509		07-Jun-1995	07-Jun-2015	CONTROLLED RELEASE BIODEGRADABLE MICRO- AND NANOSPHERES CONTAINING CYCLOSPORIN
02.1301.US	4	CON	USA	5364620	07/921,459		28-Jul-1992	15-Nov-2011	CONTROLLED ABSORPTION DILTIAZEM FORMULATION FOR ONCE-DAILY ADMINISTRATION
02.1301.US	5	DIV	USA	5616345	08/334,864		04-Nov-1994	01-Apr-2014	CONTROLLED ABSORPTION DILTIAZEM FORMULATION FOR ONCE-DAILY ADMINISTRATION
02.1303.US	3	CON	USA	5336504	08/064,401		19-May-1993	22-Jul-2012	DILTIAZEM FORMULATION AND METHODS OF TREATMENT
02.1806.US	2	CON	USA	5370879	08/073,651		07-Jun-1993	06-Dec-2011	FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
02.1806.US	3	DIV	USA	5540938	08/328,165		24-Oct-1994	30-Jul-2013	FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
02.1806.US	4	DIV	USA	5580580	08/479,506		07-Jun-1995	03-Dec-2013	FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
02.1807.US		ORD	USA	5533995	08/244,094		13-May-1994	09-Jul-2013	PASSIVE TRANSDERMAL DEVICE WITH CONTROLLED DRUG DELIVERY
02.1809K.US	2	ORD	USA	6066339	08/977,965		25-Nov-1997	25-Nov-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
02.1816E.US	2	CON	USA	6228398	09/566,636		08-May-2000	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
02.1816E.US	3	CON	USA	6730325	09/850,425	US 2002-0054907 A1	07-May-2001	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPHENIDATE)
02.1816E.US	4	CON	USA	6902742	10/331,754	US 2003-0129237 A1	30-Dec-2002	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPHENIDATE)
02.1816E.US	5	CON	USA	6793936	10/354,483	US 2003-0170304 A1	30-Jan-2003	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPHENIDATE)
02.1816E.US	6	CON	USA		10/827,689	US 2004-0197405 A1	19-Apr-2004	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPHENIDATE)
02.1816E.US	7	CIP	USA		11/372,857	US 2006-0240105 A1	10-Mar-2006	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYPHENIDATE)

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
02.1819.US	2	ORD	USA	7465462	09/744,169		19-Apr-2001	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTININ REUPTAKE INHIBITOR FORMULATIONS
02.1830.US	2	ORD	USA	7021163	10/492,098	US 2005-0003550 A1	08-Apr-2004	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM PHARMACEUTICALS
02.1832AC.US	5	DIV	USA		12/626,001	US 2010-0272807	25-Nov-2009		SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
02.1832AC.US	6	DIV	USA		12/626,085	US 2010-0272796	25-Nov-2009		SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
02.1832AC.US	7	DIV	USA		12/626,036	US 2010-0272795	25-Nov-2009		SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
02.1900.US	2	ORD	USA		11/568,891	US 2010-0136106 A1	15-Jan-2010	07-Jun-2026	MODIFIED RELEASE FAMCICLOVIR COMPOSITIONS
02.1902.US	2	ORD	USA		11/569,481	US 2009-0297597 A1	21-Nov-2006		MODIFIED RELEASE TICLOPIDINE COMPOSITIONS
02.2006.US		ORD	PCT		PCT/US2011/027736		10-Mar-2011		ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS
02.2006.US	6	ORD	USA		13/044,225		09-Mar-2011		ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS
03.0001.		ORD	Argentina	AR 255241	AR 255241		24-Jan-1992	24-Sep-2016	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Australia	654836	654836	AU1014792	13-Jan-1992	13-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Canada	2059432	2059432		15-Jan-1992	15-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Chile	46,768	92/074		24-Jan-1992	23-Jul-2025	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Finland	108333	108333		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Hungary	221,586 B1	221586		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Ireland	83410	92-0217		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Israel	100754	100754		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Japan	3602546B2	1992-011226		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Korea, Republic of	200061	200061		25-Jan-1992	25-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Mexico	176345	176345		23-Jan-1992	23-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	New Zealand	241362	241362		22-Jan-1992	22-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Norway	303668	303668		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Russian Federation	2066553	2066553		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Singapore	55104	55104		20-Jan-1992	20-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0001.		ORD	Taiwan	NI-071312	NI-071312		24-Jan-1992	24-Jan-2012	SURFACE MODIFIED DRUG NANOPARTICLES
03.0002.		ORD	Israel	107054	107054		20-Sep-1993	20-Sep-2013	IODINATED AROYLOXY CARBOXAMIDES
03.0002.		ORD	Korea, Republic of	300358	93/21154		13-Oct-1993	13-Oct-2013	IODINATED AROYLOXY CARBOXAMIDES
03.0002.		ORD	Taiwan	NI-072517	NI-072517		13-Oct-1993	13-Oct-2013	IODINATED AROYLOXY CARBOXAMIDES
03.0006.		ORD	EPC	498482	92200152.4	498482	20-Jan-1992	20-Jan-2012	X-RAY CONTRAST COMPOSITIONS USEFUL IN MEDICAL IMAGING
03.0006.		EPC	France	498482	92200152.4	498482	20-Jan-1992	20-Jan-2012	X-RAY CONTRAST COMPOSITIONS USEFUL IN MEDICAL IMAGING
03.0006.		EPC	Germany	69229925.4	92200152.4	498482	20-Jan-1992	20-Jan-2012	X-RAY CONTRAST COMPOSITIONS USEFUL IN MEDICAL IMAGING

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0006.		EPC	Italy	498482	92200152.4	498482	20-Jan-1992	20-Jan-2012	X-RAY CONTRAST COMPOSITIONS USEFUL IN MEDICAL IMAGING
03.0006.		EPC	United Kingdom	498482	92200152.4	498482	20-Jan-1992	20-Jan-2012	X-RAY CONTRAST COMPOSITIONS USEFUL IN MEDICAL IMAGING
03.0017.		ORD	Canada	2098242	2098242	2098242	11-Jun-1993	11-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017.		ORD	EPC	EP 0 577 215	93201883.1	EP 0 577 215	29-Jun-1993	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017.		EPC	France	EP 0 577 215	93201883.1	EP 0 577 215	29-Jun-1993	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017.		EPC	Germany	69328136	93201883.1	EP 0 577 215	29-Jun-1993	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017.		EPC	Italy	EP 0 577 215	93201883.1	EP 0 577 215	29-Jun-1993	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017.	2	DIV	Japan		2008-138475		29-Jun-1993	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017.	3	DIV	Japan		2010-186927	2010-265324	24-Aug-2010	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017.		ORD	Mexico	205097	933950		30-Jun-1993	30-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0017.		EPC	United Kingdom	EP 0 577 215	93201883.1	EP 0 577 215	29-Jun-1993	29-Jun-2013	PROCESS FOR OBTAINING SURFACE MODIFIED ANTICANCER NANOPARTICLES
03.0019.		ORD	Canada	2108192	2108192	2108192	12-Oct-1993	12-Oct-2013	THE USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
03.0019.		ORD	EPC	EP 0 602 702	93203365.7	EP 0 602 702	01-Dec-1993	01-Dec-2013	THE USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
03.0019.		EPC	France	602702	93203365.7	602702	01-Dec-1993	01-Dec-2013	THE USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
03.0019.		EPC	Germany	69324456.9	93203365.7	602702	01-Dec-1993	01-Dec-2013	THE USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
03.0019.		ORD	Korea, Republic of	320390	22700/93		29-Oct-1993	29-Oct-2013	THE USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
03.0019.		EPC	United Kingdom	602702	93203365.7	602702	01-Dec-1993	01-Dec-2013	THE USE OF TYLOXAPOL AS A NANOPARTICLE STABILIZER AND DISPERSANT
03.0026.		ORD	Argentina	251001	326206		04-Oct-1993	16-Sep-2012	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.		ORD	Australia	660852	48670/93		29-Sep-1993	29-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.		EPC	Austria	E193646	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.		EPC	Belgium	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.		ORD	Canada	2107400	2107400	2107400	30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0026.	ORD		Czech Republic	284802	PV02277-93		26-Oct-1993	26-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	EPC		Denmark	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	ORD		EPC	EP 0 600 528	93202795.6	EP 0 600 528	30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	ORD		Finland	108399	934320		01-Oct-1993	01-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	EPC		France	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	EPC		Germany	69328815.9	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	EPC		Greece	20000401912	3034227		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	ORD		Hungary	210928	P9302779	67644	01-Oct-1993	01-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	EPC		Ireland	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	EPC		Italy	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	ORD		Korea, Republic of	312798	22264/93		26-Oct-1993	26-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	EPC		Liechtenstein	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	EPC		Luxembourg	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	ORD		Malaysia	MY-109419A	P19302059		08-Oct-1993	08-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	ORD		Mexico	189779	936443		15-Oct-1993	15-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	EPC		Monaco	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	EPC		Netherlands	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	ORD		New Zealand	248813	248813		29-Sep-1993	29-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	ORD		Philippines	31118	47059		11-Oct-1993	23-Feb-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	EPC		Portugal	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	ORD		Slovakia	281078	PV1301/93		19-Nov-1993	19-Nov-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.	EPC		Spain	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0026.		EPC	Sweden	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.		EPC	Switzerland	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.		ORD	Taiwan	NI-069476	82108254		06-Oct-1993	06-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.		ORD	Ukraine		93003406		28-Oct-1993	28-Oct-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.		EPC	United Kingdom	EP 0 600 528	93202795.6		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0026.		ORD	Venezuela	55510	1484/93		30-Sep-1993	30-Sep-2013	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0027.		PCT	Canada	2212779	2212779		18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0027.		PCT	EPC	EP 0 808 156	96905181.2	EP 0 808 156	18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0027.		EPC	France	EP 0 808 156	96905181.2	EP 0 808 156	18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0027.		EPC	Germany	EP 0 808 156	96905181.2	EP 0 808 156	18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0027.		EPC	Italy	EP 0 808 156	96905181.2	EP 0 808 156	18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0027.		PCT	Japan	3710818	1996-8524268		18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0027.		EPC	United Kingdom	EP 0 808 156	96905181.2	EP 0 808 156	18-Jan-1996	18-Jan-2016	COMPOSITIONS COMPRISING NANOPARTICLES OF NSAI
03.0032.		PCT	Canada	2118517	2118517		01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032.		PCT	EPC	EP 0 644 755	93914224.6	EP 0 644 755	01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032.		EPC	France	644755	93914224.6	644755	01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032.		EPC	Germany	69309056.1	93914224.6	644755	01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032.		EPC	Italy	644755	93914224.6	644755	01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032.		PCT	Japan	4439590	Hei06-501515	2008-501073	09-Jun-1993	09-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032.		ORD	Mexico	203188	933452		01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0032.		EPC	United Kingdom	EP 0 644 755	93914224.6	EP 0 644 755	01-Jun-1993	01-Jun-2013	SURFACE MODIFIED NSAI NANOPARTICLES
03.0035.		PCT	Canada	2213663	2213663		22-Feb-1996	22-Feb-2016	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES
03.0035.		PCT	EPC	EP 0 810 855	96907083.8	EP 0 810 855	22-Feb-1996	22-Feb-2016	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES
03.0035.		EPC	France	810855	96907083.8	810855	22-Feb-1996	22-Feb-2016	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES
03.0035.		EPC	Germany	69628640	96907083.8	EP 0 810 855	22-Feb-1996	22-Feb-2016	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES
03.0035.		EPC	Italy	810855	96907083.8	810855	22-Feb-1996	22-Feb-2016	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0035.	EPC	United Kingdom	EP 0 810 855	96907083.8	EP 0 810 855	22-Feb-1996	22-Feb-2016	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES
03.0038.	PCT	Canada	2212803	2212803	KOPROOM2	09-Feb-1996	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038.	PCT	EPC	812187	96904612.7	812187	09-Feb-1996	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038.	EPC	France	812187	96904612.7	812187	09-Feb-1996	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038.	EPC	Germany	69627835	96904612.7	EP 0 812 187	09-Feb-1996	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038.	EPC	Italy	812187	96904612.7	812187	09-Feb-1996	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038.	PCT	Japan		1996-8525046		09-Feb-1996	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038.	3 DIV	Japan		2010-145720	2010-241820	28-Jun-2010	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0038.	EPC	United Kingdom	EP 0 812 187	96904612.7	EP 0 812 187	09-Feb-1996	09-Feb-2016	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
03.0053.	ORD	Argentina	AR253558	331937		04-May-1995	25-Aug-2014	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.	EPC	Austria	E208191	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.	EPC	Belgium	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.	PCT	Canada	2190134	2190134	2190134	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.	EPC	Denmark	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.	PCT	EPC	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.	EPC	France	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.	EPC	Germany	69523781	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.	EPC	Greece	20020400382	3038147	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.	EPC	Ireland	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.	ORD	Israel	113851	113851		25-May-1995	25-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.	EPC	Italy	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.	PCT	Japan	3607294	1995-530317		08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0053.		EPC	Luxembourg	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.		ORD	Malaysia	MY-113569-A	P195001375		25-May-1995	30-Apr-2017	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.		EPC	Monaco	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.		EPC	Netherlands	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.		ORD	Philippines	31497	50574		24-May-1995	03-Nov-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.		EPC	Portugal	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.		EPC	Spain	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.		EPC	Sweden	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.		EPC	Switzerland	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.		ORD	Taiwan	NI-142783	84103642	460297	13-Apr-1995	13-Apr-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.		EPC	United Kingdom	EP 0 804 161	95919062	EP 0 804 161	08-May-1995	08-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0053.		ORD	Venezuela	56956	0854-95	413	25-May-1995	25-May-2015	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0055.		PCT	Canada		2213660	2213660	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.		PCT	EPC	EP 0 810 854	96906567.1	EP 0 810 854	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.	2	DIV	EPC	EP 1 354 583	3016236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.		EPC	France	EP 0 810 854	96906567.1	EP 0 810 854	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.	2	DIV	France	EP 1 354 583	3016236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.		EPC	Germany	69630207	96906567.1	EP 0 810 854	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.	2	DIV	Germany	69637288	3016236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.	2	DIV	Ireland	EP 1 354 583	3016236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.		EPC	Italy	EP 0 810 854	96906567.1	EP 0 810 854	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.	2	DIV	Italy	EP 1 354 583	3016236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0055.	PCT	Japan	4484248	1996-8525799		23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.	2 DIV	Spain	EP 1 354 583	3016236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.	EPC	United Kingdom	EP 0 810 854	96906567.1	EP 0 810 854	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0055.	2 DIV	United Kingdom		3016236.6	EP 1 354 583	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICULATE DISPERSIONS
03.0056.	PCT	Canada	2232879	2232879	2232879	25-Sep-1996	25-Sep-2016	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
03.0056.	PCT	EPC		96932321.1	EP 0 859 604	25-Sep-1996	25-Sep-2016	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
03.0056.	2 DIV	EPC		10181619.7	EP 2 275 094	29-Sep-2010	25-Sep-2016	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
03.0057.	ORD	Argentina	AR 254497 V1	331938		04-May-1995	29-Sep-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Austria	196601	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Belgium	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	PCT	Canada	2190966	2190966	2190966	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Denmark	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	PCT	EPC	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	France	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Germany	69518981.6	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Greece	3035040	3035040	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Ireland	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	ORD	Israel	113852	113852		25-May-1995	25-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Italy	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Liechtenstein	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0057.	EPC	Luxembourg	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	ORD	Malaysia	MY-112458-A	P195001374		24-May-1995	30-Jun-2016	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Monaco	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Netherlands	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	ORD	Philippines	11995-50573	1-1995-50573		24-May-1995	02-Mar-2018	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Portugal	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Spain	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Sweden	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	Switzerland	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	ORD	Taiwan	NI-112433	84104440	384224	03-May-1995	03-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	EPC	United Kingdom	EP 0 760 653	95919828.4	EP 0 760 653	12-May-1995	12-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0057.	ORD	Venezuela	57612	0853-95		25-May-1995	25-May-2015	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
03.0058.	ORD	Argentina	253686	253686		24-Feb-1995	09-Sep-2014	POLYOXYALKYLENE BLOCK COPOLYMERS AND A PROCESS FOR PREPARING THEM
03.0058.	PCT	Canada	2207589	2207589	2207589	21-Dec-1994	21-Dec-2014	POLYETHER COPOLYMERS AND A PROCESS FOR PREPARING THEM
03.0058.	ORD	Israel	112136	112136		23-Dec-1994	23-Dec-2014	POLYETHER COPOLYMERS AND A PROCESS FOR PREPARING THEM
03.0058.	ORD	Mexico	203191	951133		28-Feb-1995	28-Feb-2015	POLYOXYALKYLENE BLOCK COPOLYMERS AND A PROCESS FOR PREPARIN G THEM
03.0058.	ORD	Philippines	11995-50830	50830		03-Jul-1995	14-Jun-2019	POLYOXYALKYLENE BLOCK COPOLYMERS AND A PROCESS FOR PREPARIN G THEM
03.0058.	ORD	United Kingdom	2283977	2283977		30-Oct-1993	30-Oct-2013	POLYETHER COPOLYMERS AND A PROCESS FOR PREPARING THEM
03.0059.	PCT	Canada	2295588	2295588	2295588	09-Jul-1998	09-Jul-2018	NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS
03.0059.	PCT	EPC	EP 1 002 065	Validation of EP		09-Jul-1998	09-Jul-2018	NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS AND METHODS OF MAKING SUCH FORMULATIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0059.		PCT	France	EP 1 002 065	Validation of EP		09-Jul-1998	09-Jul-2018	NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS AND METHODS OF MAKING SUCH FORMULATIONS
03.0059.		PCT	Germany	69831677	98931809.2		09-Jul-1998	09-Jul-2018	NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS AND METHODS OF MAKING SUCH FORMULATIONS
03.0059.		PCT	Italy	EP 1 002 065	Validation of EP		09-Jul-1998	09-Jul-2018	NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS AND METHODS OF MAKING SUCH FORMULATIONS
03.0059.		PCT	Japan		2000-502163	2010-47579	09-Jul-1998	09-Jul-2018	NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS AND METHODS OF MAKING SUCH FORMULATIONS
03.0059.	2	DIV	Japan		2009-229598		09-Jul-1998	09-Jul-2018	NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS AND METHODS OF MAKING SUCH FORMULATIONS
03.0059.		PCT	United Kingdom	EP 1 002 065	Validation of EP		09-Jul-1998	09-Jul-2018	NANOCRYSTALLINE FORMULATIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS USING CELLULOSIC SURFACE STABILIZERS AND METHODS OF MAKING SUCH FORMULATIONS
03.0060.		PCT	Canada	2 340 221	2 340 221	2 340 221	12-Aug-1999	12-Aug-2019	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
03.0060.		PCT	EPC	EP 1 105 109	99941065.7	EP 1 105 109	12-Aug-1999	12-Aug-2019	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
03.0060.		EPC	France	EP 1 105 109	99941065.7	EP 1 105 109	12-Aug-1999	12-Aug-2019	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
03.0060.		EPC	Germany	69907213	99941065.7	EP 1 105 109	12-Aug-1999	12-Aug-2019	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
03.0060.		EPC	Italy	EP 1 105 109	99941065.7	EP 1 105 109	12-Aug-1999	12-Aug-2019	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
03.0060.		EPC	United Kingdom	EP 1 105 109	99941065.7	EP 1 105 109	12-Aug-1999	12-Aug-2019	INJECTABLE FORMULATIONS OF NANOPARTICULATE NAPROXEN
03.0061.		PCT	Canada	2342309	2342309	2342309	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN
03.0061.		PCT	EPC	EP 1 109 536	99943733.8	EP 1 109 536	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN
03.0061.		EPC	France	EP 1 109 536	99943733.8	EP 1 109 536	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN
03.0061.		EPC	Germany	EP 1 109 536	DE19996002046	DE69902046D	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPROXEN

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0061.		EPC	Italy	EP 1 109 536	99943733.8	EP 1 109 536	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPIROXEN
03.0061.		PCT	Japan	3802345	2000-568481T	2002-524413T	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPIROXEN
03.0061.		EPC	United Kingdom	EP 1 109 536	99943733.8	EP 1 109 536	19-Aug-1999	19-Aug-2019	NEW SOLID DOSE FORM OF NANOPARTICULATE NAPIROXEN
03.0062.		PCT	Canada	2213638	2213638	KOPROOM2	23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS
03.0062.		PCT	Japan	4484247	Hei08-525798		23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS
03.0062.	2	DIV	Japan		2007-230718		23-Feb-1996	23-Feb-2016	AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS
03.0063.		EPP	Austria	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Belgium	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		PCT	Canada	2350074	2350074	2350074	12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Cyprus, Republic of	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Denmark	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		PCT	EPC	EP 1 128 814	99956981.7	EP 1 128 814	27-Sep-2010	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.	2	DIV	EPC		10179894	EP 2 263 652	12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Finland	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	France	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Germany	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Greece	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Ireland	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Italy	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		PCT	Japan		2000-580594		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Liechtenstein	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Luxembourg	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Monaco	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Netherlands	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Portugal	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Spain	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Sweden	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	Switzerland	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0063.		EPP	United Kingdom	EP 1 128 814	99956981.7		12-Nov-1999	12-Nov-2019	AEROSOLS COMPRISING NANOPARTICLE DRUGS
03.0064.		PCT	Canada	2362508	2362508	KOPROOM2	14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
03.0064.		PCT	EPC	EP 1 156 788	9134448.7	EP 1 156 788	14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
03.0064.		EPC	France	EP 1 156 788	9134448.7	EP 1 156 788	14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
03.0064.		EPC	Germany	EP 1 156 788	9134448.7	EP 1 156 788	14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
03.0064.		EPC	Italy	EP 1 156 788	9134448.7	EP 1 156 788	14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
03.0064.		PCT	Japan	4380925	2000-602040		14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Case	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0064.	EPC		United Kingdom	EP 1 156 788	913448.7	EP 1 156 788	14-Feb-2000	14-Feb-2020	USE OF PEG-DERIVATIZED LIPIDS AS SURFACE STABILIZERS FOR NANOPARTICULATE COMPOSITIONS
03.0065.	PCT		Canada	2367096	2367096	2367096	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0065.	PCT		EPC	EP 1 161 229	910167.6	EP 1 161 229	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0065.	EPC		France	EP 1 161 229	910167.6	EP 1 161 229	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0065.	EPC		Germany	60000823	910167.6	EP 1 161 229	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0065.	EPC		Italy	EP 1 161 229	910167.6	EP 1 161 229	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0065.	PCT		Japan		2000-603653		14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0065.	DIV	2	Japan		2009-223800	2010-31026	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0065.	EPC		United Kingdom	EP 1 161 229	910167.6	EP 1 161 229	14-Feb-2000	14-Feb-2020	METHODS FOR PREVENTING CRYSTAL GROWTH AND PARTICLE AGGREGATION IN NANOPARTICULATE COMPOSITIONS
03.0066.	PCT		Canada	2384670	2384670	2384670	07-Sep-2000	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0066.	PCT		EPC	EP 1 210 104	959985.5	EP 1 210 104	07-Sep-2000	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0066.	PCT		France	EP 1 210 104	Validation of EP		07-Sep-2000	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0066.	PCT		Germany	60027171	Validation of EP		07-Sep-2000	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0066.	PCT		Italy	EP 1 210 104	Validation of EP		07-Sep-2000	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0066.	ORD		Japan		2001-521335		07-Sep-2000	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0066.	2	DIV	Japan		2010-186933	2011-006450	22-Sep-2010	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0066.		PCT	United Kingdom	EP 1 210 104	Validation of EP		07-Sep-2000	07-Sep-2020	NANOPARTICULATE COMPOSITIONS COMPRISING AMORPHOUS CYCLOSPORINE AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
03.0067.		PCT	Canada	2346001	2346001	2346001	01-Oct-1999	01-Oct-2019	CONTROLLED RELEASE NANOPARTICULATE COMPOSITIONS
03.0067.		PCT	EPC		99950105.9	EP 1 117 384	01-Oct-1999	01-Oct-2019	CONTROLLED RELEASE NANOPARTICULATE COMPOSITIONS
03.0067.	2	DIV	EPC		10179341.2	EP 2 266 542	24-Sep-2010	01-Oct-2019	CONTROLLED RELEASE NANOPARTICULATE COMPOSITIONS
03.0067.	DIV	DIV	Japan		2008-227248	2009-019056	01-Oct-1999	01-Oct-2019	CONTROLLED RELEASE NANOPARTICULATE COMPOSITIONS
03.0068.		PCT	Canada	2386782	2386782	2386782	05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068.		PCT	EPC	EP 1 217 993	970579.9	EP 1 217 993	05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068.		EPC	France	EP 1 217 993	970579.9	EP 1 217 993	05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068.		EPC	Germany	60019774.3	970579.9	1217993	05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068.		EPC	Italy	EP 1 217 993	970579.9	EP 1 217 993	05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068.		PCT	Japan	4394324	2001-529425		05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068.	2	DIV	Japan		2009-135738		05-Jun-2009	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0068.		EPC	United Kingdom	EP 1 217 993	970579.9	EP 1 217 993	05-Oct-2000	05-Oct-2020	BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS
03.0069.		PCT	Canada	2393195	2393195	2393195	31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069.		PCT	EPC	EP 1 185 371	937882.9		31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069.		PCT	France	EP 1 185 371	937882		31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069.		PCT	Germany	60012520	Validation of EP		31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069.		PCT	Ireland	EP 1 185 371	937882.9		31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069.		PCT	Italy	EP 1 185 371	Validation of EP		31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069.		PCT	Japan	4156807	2000-621075		31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0069.		PCT	United Kingdom	EP 1 185 371	Validation of EP		31-May-2000	31-May-2020	SMALL-SCALE MILL AND METHOD THEREOF
03.0070.		PCT	Canada	2408848	2408848	2408848	18-May-2001	18-May-2021	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
03.0070.		PCT	EPC	EP 1 282 399	1937497.4		18-May-2001	18-May-2021	RAPIDLY DISINTEGRATING DOSAGE FORM
03.0070.		PCT	France	EP 1 282 399	Validation of EP		18-May-2001	18-May-2021	RAPIDLY DISINTEGRATING DOSAGE FORM
03.0070.		PCT	Germany	60121570	Validation of EP		18-May-2001	18-May-2021	RAPIDLY DISINTEGRATING DOSAGE FORM
03.0070.		PCT	Italy		Validation of EP		18-May-2001	18-May-2021	RAPIDLY DISINTEGRATING DOSAGE FORM
03.0070.		PCT	Japan		2001-583733		18-May-2001	18-May-2021	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0070.	2	DIV PCT	Japan United Kingdom		2010-227452 Validation of EP		18-May-2001 18-May-2001	18-May-2021 18-May-2021	RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM RAPIDLY DISINTEGRATING DOSAGE FORM SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.		EPP	Austria	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.		EPP	Belgium	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.		PCT	Canada	2416109	2416109	2416109	04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.		EPP	Cyprus, Republic of	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.		EPP	Denmark	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.		PCT	EPC	EP 1 318 788	1975724.4	EP 1 318 788	04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.		EPP	Finland	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.		EPP	France	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.		EPP	Germany	60131991	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.		EPP	Greece	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.		EPP	Ireland	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.		EPP	Italy	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0071.	PCT	Japan	4460827	2002-528199		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS
03.0071.	EPP	Liechtenstein	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.	EPP	Luxembourg	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.	EPP	Monaco	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.	EPP	Netherlands	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.	EPP	Portugal	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.	EPP	Spain	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.	EPP	Sweden	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.	EPP	Switzerland	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.	EPP	Turkey	200801680	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0071.	EPP	United Kingdom	EP 1 318 788	1975724.4		04-Sep-2001	04-Sep-2021	SOLID DOSE NANOPARTICULATE COMPOSITIONS COMPRISING A SYNERGISTIC COMBINATION OF A POLYMERIC SURFACE STABILIZER AND DIOCTYL SODIUM SULFOSUCCINATE
03.0072.	EPC	Belgium	EP 1 341 521	EP 1 341 521		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0072.		PCT	Canada		2428785	2428785	16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABILIZERS
03.0072.		PCT	EPC	EP 1 341 521	1274072.6	EP 1 341 521	16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072.		PCT	France	EP 1 341 521	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072.		EPC	Germany	60137362.6	60137362.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072.		PCT	Ireland	EP 1 341 521	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072.		PCT	Italy	EP 1 341 521	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072.		PCT	Japan	4541647	2002-590934		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072.		PCT	Liechtenstein	EP 1 341 521	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072.		EPP	Spain	ES 2317874 T3	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072.		EPC	Switzerland	EP 1 341 521	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0072.		PCT	United Kingdom	EP 1 341 521	1274072.6		16-Nov-2001	16-Nov-2021	NANOPARTICULATE COMPOSITIONS COMPRISING A DRUG AND COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABLE
03.0077.		PCT	Austria	453454	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Belgium	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Canada	2406696	2406696	2406696	26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Cyprus, Republic of	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Denmark	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	EPC	EP 1 313 564	1930812.1	EP 1 313 564	26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Finland	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	France	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Germany	60140947	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Greece	3071059	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Ireland	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0077.		EPC	Italy	N.21976BE/2010	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Japan	4343476	2001-581993		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Liechtenstein	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Luxembourg	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Monaco	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Netherlands	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Portugal	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Spain	2334435	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Sweden	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Switzerland	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	Turkey	TR 2010 00985 T4	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0077.		PCT	United Kingdom	EP 1 313 564	EP Validation		26-Apr-2001	26-Apr-2021	APPARATUS FOR SANITARY WET MILLING
03.0078.		EPC	Austria	EP 1 429 731	EP 1 429 731		19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		EPC	Belgium	EP 1 429 731	EP 1 429 731		19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		PCT	Canada	EP 1 429 731	2460867	2460867	19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		EPC	Cyprus, Republic of	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		EPC	Denmark	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	EPC	EP 1 429 731	2775863	1429731	19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	Finland	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	France	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		EPC	Germany	60217367.1			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	Greece	20070400953			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	Ireland	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	Italy	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	Japan	4464129	2003-528522		19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	Luxembourg	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	Monaco	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	Netherlands	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	Portugal	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	Spain	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	Sweden	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		EPC	Switzerland	EP 1 429 731	2775863		19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0078.		ORD	United Kingdom	EP 1 429 731			19-Sep-2002	19-Sep-2022	NANOPARTICULATE INSULIN FORMULATIONS
03.0079.		EPP	Austria	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Belgium	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		PCT	Canada	2449490	2449490	2449490	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Cyprus, Republic of	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Denmark	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		PCT	EPC	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Finland	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	France	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Germany	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0079.		EPP	Greece	20080402576	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Ireland	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Italy	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		PCT	Japan	4223390	2003-501597		31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Liechtenstein	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Luxembourg	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Monaco	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Netherlands	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Portugal	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Spain	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Sweden	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Switzerland	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	Turkey	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0079.		EPP	United Kingdom	EP 1 392 441	2739588.8	EP 1 392 441	31-May-2002	31-May-2022	SYSTEM AND METHOD FOR MILLING MATERIALS
03.0080.	DIV	DIV	EPC		7011731.2	EP1 829 530	15-Jun-2007	13-Sep-2022	STABILIZATION OF ACTIVE AGENTS BY FORMULATION INTO NANOPARTICULATE FORM
03.0083.		PCT	Austria	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Belgium	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Bulgaria	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Canada		2475092	2475092	04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Czech Republic	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Denmark	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	EPC	EP 1 471 887	3737537.5	EP 1 471 887	04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Finland	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	France	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Germany	60332212	60332212.3	EP 1 471 887	04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Greece	3072191	03 737 537.5-1219	EP 1 471 887	04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Hungary	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Ireland	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Italy	EP 1 471 887	IT 25422BE/2010		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0083.		PCT	Japan	4598399	2003-565446	Patent Pub Date	04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Liechtenstein	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Netherlands	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Portugal	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Slovakia	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Spain	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Sweden	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	Switzerland	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0083.		PCT	United Kingdom	EP 1 471 887	EP Validation		04-Feb-2003	04-Feb-2023	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER
03.0084.		PCT	EPC	EP 1 401 401	1401401		24-Jun-2002	24-Jun-2022	METHOD FOR HIGH THROUGH PUT SCREENING USING A SMALL SCALE MILL OR MICROFLUIDICS
03.0084.		PCT	France	EP 1 401 401	2756105		24-Jun-2002	24-Jun-2022	METHOD FOR HIGH THROUGH PUT SCREENING USING A SMALL SCALE MILL OR MICROFLUIDICS
03.0084.		PCT	Italy	EP 1 401 401	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086.		PCT	Canada	2479737	2479737	2479737	20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086.		PCT	EPC	EP 1 490 025	3723782.3	EP 1 490 025	20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086.		EPP	France	EP 1 490 025	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086.		EPP	Germany	60319073.1	3723782.3	DE 603 19 073 T2	20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086.		EPP	Hungary	E003331	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086.		EPP	Ireland	EP 1 490 025	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086.		EPP	Italy	24017BE/2008	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086.		PCT	Japan	4611641	2003-577854		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086.		EPP	Liechtenstein	EP 1 490 025	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0086.		EPP	Spain	EP 1 490 025	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086.		EPP	Switzerland	EP 1 490 025	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0086.		EPP	United Kingdom	EP 1 490 025	3723782.3		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS
03.0087.		PCT	Canada		2479735	2479735	20-Mar-2003	20-Mar-2023	FAST DISSOLVING DOSAGE FORMS HAVING REDUCED FRIABILITY
03.0087.		PCT	EPC		3718010.6	EP 1 487 419	20-Mar-2003	20-Mar-2023	FAST DISSOLVING DOSAGE FORMS HAVING REDUCED FRIABILITY
03.0087.		PCT	Japan		2003-577853		20-Mar-2003	20-Mar-2023	FAST DISSOLVING DOSAGE FORMS HAVING REDUCED FRIABILITY
03.0087.	2	DIV	Japan		2010-178286		20-Mar-2003	20-Mar-2023	FAST DISSOLVING DOSAGE FORMS HAVING REDUCED FRIABILITY
03.0088.		EPC	Belgium	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088.		PCT	Canada		2472582	2472582	31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088.		PCT	EPC	EP 1 478 342	2806274.3	EP 1 478 342	31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088.		EPC	France	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088.		EPC	Germany	60235411	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088.		EPC	Ireland	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088.		EPC	Italy	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088.		PCT	Japan	4623966	2003-577552		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088.		EPC	Liechtenstein	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088.		EPC	Spain	EP 1 478 342	ES 1 478 342		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0088.		EPC	Switzerland	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0088.		EPC	United Kingdom	EP 1 478 342	EP Validation		31-Dec-2002	31-Dec-2022	STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER
03.0089.		EPP	Austria	E 487470	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Belgium	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Bulgaria	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		PCT	Canada		2498207	2498207	11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Cyprus, Republic of	CY201011010 84	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Czech Republic	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Denmark	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		PCT	EPC	EP 1 553 927	3816299.6	EP 1 553 927	11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Estonia	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Finland	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	France	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Germany	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Greece	3073488	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Hungary	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Ireland	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Italy	N.20214BE/20 11	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		PCT	Japan		2005-503259		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Liechtenstein	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Luxembourg	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0089.		EPP	Monaco	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Netherlands	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Portugal	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Romania	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Slovakia	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Slovenia	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Spain	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Sweden	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Switzerland	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	Turkey	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0089.		EPP	United Kingdom	EP 1 553 927	EP Validation		11-Sep-2003	11-Sep-2023	GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
03.0091.	AR2	ORD	Argentina		90100919		13-Mar-2009	13-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	AU2	ORD	Australia		2009-223108		27-Aug-2010	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.		ORD	Canada		2479665	2479665	20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	CA2	ORD	Canada		2718189		09-Sep-2010	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.		ORD	EPC	EP 1 490 030	3723781.5	EP 1 490 030	20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.		EPP	France	EP 1 490 030	3723781.5		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.		EPP	Germany	EP 1 490 030	EP 1 490 030		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.		EPP	Ireland	EP 1 490 030	3723781.5		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	IL2	ORD	Israel		207893		12-Mar-2009	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.		EPP	Italy	EP 1 490 030	EP 1 490 030		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.		ORD	Japan		2003-577857		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0091.	2 DIV	Japan		2009-266089		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	JP2 ORD	Japan		2010-550868		10-Sep-2010	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	KR2 ORD	Korea, Republic of		10-2010-7021510		12-Mar-2009	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	MX2 ORD	Mexico		MX/a/2010/009866		12-Mar-2009	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	NZ2 ORD	New Zealand		587658		12-Mar-2009	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	PK2 ORD	Pakistan		229/2009		13-Mar-2009	13-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	WO2 ORD	PCT		PCT/US2009/036965	WO/2009/114695 A1	12-Mar-2009	12-Mar-2013	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	SG2 ORD	Singapore		2010-06315-4		31-Aug-2010	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	ZA2 ORD	South Africa		2010/06346		12-Mar-2009	12-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	EPP	Switzerland	EP 1 490 030	3723781.5		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	TW2 ORD	Taiwan		98108213	200942272	13-Mar-2009	13-Mar-2029	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0091.	EPP	United Kingdom	EP 1 490 030	EP 1 490 030		20-Mar-2003	20-Mar-2023	NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0092.	2 PCT	Australia		2006262144		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092.	2 PCT	Brazil		PI0612665-0		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092.	2 PCT	Canada		2481390	2481390	14-Apr-2003	14-Apr-2023	NANOPARTICULATE FORMULATIONS OF MEGESTROL
03.0092.	2 PCT	Canada		2613466		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092.	2 PCT	China (People's Republic)		2006800304		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092.	ORD	EPC		3723991	EP 1 494 649	14-Apr-2003	14-Apr-2023	NANOPARTICULATE FORMULATIONS OF MEGESTROL
03.0092.	DIV	EPC		10010939.6		27-Sep-2010	14-Apr-2023	NANOPARTICULATE FORMULATIONS OF MEGESTROL
03.0092.	2 PCT	Eurasian Patent Organization		200800099		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092.	2 PCT	Israel		188322		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092.	2 PCT	Japan		2003-583377		14-Apr-2003	14-Apr-2023	NANOPARTICULATE FORMULATIONS OF MEGESTROL
03.0092.	2 DIV	Japan		2010-140607	2010-248220	14-Apr-2003	14-Apr-2023	NANOPARTICULATE FORMULATIONS OF MEGESTROL
03.0092.	3 PCT	Japan		2008-518396		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092.	2 PCT	Korea, Republic of		2008-7001652		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092.	2 PCT	Mexico		MX/A/2008/000396		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092.	2 PCT	Norway		20080403		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092.	2 PCT	Singapore		200718865-9		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092.	SG2DI V	Singapore		201009704-6		29-Dec-2010	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS
03.0092.	2 PCT	South Africa	2008/00376	2008-00376		22-Jun-2006	22-Jun-2026	NANOPARTICULATE MEGESTROL FORMULATIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0093.	2	ORD	Argentina	2487054	90101116		27-Mar-2009		NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
03.0093.		PCT	Canada	2487054	2487054	2487054	23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093.	2	PCT	Canada		2719811	2719811	27-Mar-2009	27-Mar-2013	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093.		PCT	EPC		3808363	EP 1 519 715	23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093.	2	PCT	EPC		9726084.8	EP 2 271 316	27-Mar-2009	27-Mar-2013	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093.		PCT	Japan	4395074	2004-549886		23-May-2003	23-May-2023	
03.0093.	2	DIV	Japan		2009-199516	2010-013462	23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093.	3	PCT	Japan		2011-502085		24-Sep-2010	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093.		ORD	Pakistan		248/2009		19-Mar-2009	19-Mar-2028	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093.	2	ORD	PCT		PCT/US2009/038490		27-Mar-2009	27-Mar-2013	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093.		ORD	Taiwan		92114057		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093.	2	ORD	Taiwan		98109709		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093.	2	ORD	Venezuela		00561-2009	201006466	20-Mar-2009	25-Mar-2029	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Algeria	3909	40366		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		ORD	Argentina		30107837		26-May-2004	26-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		EUC	Armenia	12842	200401556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	2	EUC	Armenia		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Australia	2003301807	2003301807		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	2	DIV	Australia		2008264174		23-May-2004	26-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		EUC	Azerbaijan	12842	200401556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	2	EUC	Azerbaijan		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		EUC	Belarus	12842	200401556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	2	EUC	Belarus		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Brazil		P10311275-6		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		ORD	Chile		1051-2003		23-May-2003	15-May-2022	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	China (People's Republic)		3817270.4		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	2	DIV	China (People's Republic)		201010144539.6	CN 101797233A	18-Mar-2010	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	4	DIV	China (People's Republic)		201010144105.6	CN 101797245A	24-Mar-2010	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Eurasian Patent Organization	12842	200401556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	2	DIV	Eurasian Patent Organization		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCX	Hong Kong		5108746.5		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	DIV	RCN	Hong Kong		11100469.9		18-Jan-2011	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	DIV3	RCN	Hong Kong		11100470.6		18-Jan-2011	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Hong Kong		11106061.8		14-Jun-2011	27-Mar-2029	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	India		3843/2004		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Indonesia		W00200402638		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Israel		165332		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		EUC	Kazakhstan	12842	200401556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	2	EUC	Kazakhstan		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Korea, Republic of		2004-7019041		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		EUC	Kyrgyz Republic	12842	200401556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0093FR.	2	EUC	Kyrgyz Republic		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		ORD	Malaysia		PI-20031929		23-May-2003	24-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Mexico	252667	2004/011653		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		EUC	Moldova	12842	2004/01556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	2	EUC	Moldova		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Morocco	27250	27964	27250	23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	New Zealand	537324	537324		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Norway		20050224		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Philippines	1-2004-501915	1-2004-501915		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	DIV	DIV	Philippines	501915	1-2008-502769		12-Dec-2008	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		EUC	Russian Federation	12842	2004/01556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	2	EUC	Russian Federation		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Singapore	108045	2004/06808-6	108045	23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	2	DIV	Singapore		2007/05850-6	159391	23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	South Africa	2004/10209	2004/10209		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		EUC	Tajikistan	12842	2004/01556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	2	EUC	Tajikistan		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		ORD	Thailand	82589			26-May-2003	26-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Tunisia	18880	SN04.230		19-Nov-2004	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		EUC	Turkmenistan	12842	2004/01556		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.	2	EUC	Turkmenistan		2009-00485		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		ORD	Uruguay		27.882		26-May-2003	26-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		ORD	Venezuela		0835-2003		26-May-2003	26-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0093FR.		PCT	Viet Nam	8283	1-2004-01371		23-May-2003	23-May-2023	NANOPARTICULATE FIBRATE FORMULATIONS
03.0095.		PCT	EPC	EP 1 503 737	3728678.8	EP 1 503 737	05-May-2003	05-May-2023	NANOPARTICULATE FORMATIONS OF NYSTATIN
03.0095.		EPP	France	EP 1 503 737	3728678.8		05-May-2003	05-May-2023	NANOPARTICULATE FORMATIONS OF NYSTATIN
03.0095.		EPP	Germany	EP 1 503 737	3728678.8		05-May-2003	05-May-2023	NANOPARTICULATE FORMATIONS OF NYSTATIN
03.0095.		EPP	Ireland	EP 1 503 737	3728678.8		05-May-2003	05-May-2023	NANOPARTICULATE FORMATIONS OF NYSTATIN
03.0095.		EPP	Liechtenstein	EP 1 503 737	3728678.8		05-May-2003	05-May-2023	NANOPARTICULATE FORMATIONS OF NYSTATIN
03.0095.		EPP	Switzerland	EP 1 503 737	3728678.8		05-May-2003	05-May-2023	NANOPARTICULATE FORMATIONS OF NYSTATIN
03.0095.		EPP	United Kingdom	EP 1 503 737	3728678.8		05-May-2003	05-May-2023	NANOPARTICULATE FORMATIONS OF NYSTATIN
03.0096.		PCT	Canada		2488499	2488499	10-Jun-2003	10-Jun-2023	NANOPARTICULATE STATIN FORMULATIONS AND NOVEL STATIN COMBINATIONS
03.0096.		PCT	EPC		3738952.5	EP 1 531 799	10-Jun-2003	10-Jun-2023	NANOPARTICULATE STATIN FORMULATIONS AND NOVEL STATIN COMBINATIONS
03.0096.		PCT	Japan		2004-510760		10-Jun-2003	10-Jun-2023	NANOPARTICULATE STATIN FORMULATIONS AND NOVEL STATIN COMBINATIONS
03.0098.		PCT	Japan	4533134	2004-510752		10-Jun-2003	10-Jun-2023	NANOPARTICULATE POLYCOSANOL FORMULATIONS AND NOVEL POLYCOSANOL COMBINATIONS
03.0099.		PCT	Belgium	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.		PCT	Canada		2517679	2517679	24-Feb-2004	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.		PCT	EPC	E005977	4785761	EP 1 617 816	08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.	2	DIV	EPC		8006465.2			24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0099.		PCT	France	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.		PCT	Germany	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.		PCT	Hungary	E005977	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.		PCT	Ireland	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.		PCT	Italy	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.		PCT	Japan		2006-532300		24-Feb-2004	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.	2	DIV	Japan		2010-233858		24-Feb-2004	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.		DIV	Japan		2011-148037		04-Jul-2011	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.		PCT	Liechtenstein	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.		PCT	Spain	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.		PCT	Switzerland	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0099.		PCT	United Kingdom	EP 1 617 816	4785761		08-Jun-2009	24-Feb-2024	NANOPARTICULATE MELOXICAM FORMULATIONS
03.0100.		PCT	Canada		2504610	2504610	12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIBLE AND COMPRISING PULLULAN
03.0100.		PCT	EPC	EP 1 585 502	3811260.3	EP 1 585 502	12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIBLE AND COMPRISING PULLULAN
03.0100.		PCT	Belgium	EP 1 585 502	EP Validation	EP 1 585 502		12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIBLE AND COMPRISING PULLULAN
03.0100.		PCT	France	EP 1 585 502	EP Validation	EP 1 585 502		13-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIBLE AND COMPRISING PULLULAN
03.0100.		PCT	Germany	EP 1 585 502	EP Validation	EP 1 585 502		14-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIBLE AND COMPRISING PULLULAN
03.0100.		PCT	Hungary	EP 1 585 502	EP Validation	EP 1 585 502		15-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIBLE AND COMPRISING PULLULAN
03.0100.		PCT	Ireland	EP 1 585 502	EP Validation	EP 1 585 502		16-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIBLE AND COMPRISING PULLULAN
03.0100.		PCT	Italy	EP 1 585 502	EP Validation	EP 1 585 502		17-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIBLE AND COMPRISING PULLULAN
03.0100.		PCT	Spain	EP 1 585 502	EP Validation	EP 1 585 502		18-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIBLE AND COMPRISING PULLULAN
03.0100.		PCT	Switzerland / Liechtenstein	EP 1 585 502	EP Validation	EP 1 585 502		19-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIBLE AND COMPRISING PULLULAN
03.0100.		PCT	United Kingdom	EP 1 585 502	EP Validation	EP 1 585 502		20-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIBLE AND COMPRISING PULLULAN
03.0100.		PCT	Japan		2004-552054		12-Nov-2003	12-Nov-2023	FAST-DISINTEGRATING SOLID DOSAGE FORMS BEING NOT FRIBLE AND COMPRISING PULLULAN
03.0102.		PCT	Canada		2492488	2492488	16-Jul-2003	16-Jul-2023	LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
03.0102.		PCT	EPC		3764723.7	EP 1 551 457	16-Jul-2003	16-Jul-2023	LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
03.0102.	2	DIV	EPC		10010944.6	EP 2 283 864	16-Jul-2003	16-Jul-2023	LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
03.0102.		PCT	Japan		2004-521891		16-Jul-2003	16-Jul-2023	LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0103.		PCT	Canada		2500908		04-Sep-2003	04-Sep-2023	GAMMA IRRADIATION OF SOLID NANOPARTICULATE ACTIVE AGENTS
03.0103.		PCT	EPC		3749342.6	EP 1 556 091	04-Sep-2003	04-Sep-2023	GAMMA IRRADIATION OF SOLID NANOPARTICULATE ACTIVE AGENTS
03.0103.		PCT	Japan		2004-543261		04-Sep-2003	04-Sep-2023	GAMMA IRRADIATION OF SOLID NANOPARTICULATE ACTIVE AGENTS
03.0106.		PCT	Canada	2513064	2513064	2513064	30-Jan-2004	30-Jan-2024	NANOPARTICULATE TOPIRAMATE FORMULATIONS
03.0106.		PCT	EPC		4706953.9	EP 1 587 499	30-Jan-2004	30-Jan-2024	NANOPARTICULATE TOPIRAMATE FORMULATIONS
03.0106.		ORD	Japan	4469846	2006-508639		30-Jan-2004	30-Jan-2024	NANOPARTICULATE TOPIRAMATE FORMULATIONS
03.0108.		PCT	Canada		2508301	2508301	23-Apr-2003	23-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
03.0108.		PCT	EPC		3724196.5	EP 1 613 276	23-Apr-2003	23-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
03.0108.	3	DIV	EPC		10011267.7	EP 2 263 651	28-Sep-2010	23-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
03.0108.		PCT	Japan		2004-570751		23-Apr-2003	23-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
03.0108.		DIV	Japan		2011-160522		22-Jul-2011	23-Apr-2023	LOW VISCOSITY LIQUID DOSAGE FORMS
03.0109.		PCT	Canada		2523035	2523035	24-May-2004	24-May-2024	STERILIZATION OF DISPERSIONS OF NANOPARTICULATE ACTIVE AGENTS WITH GAMMA RADIATION
03.0109.		PCT	EPC		4751758.6	EP 1 626 742	24-May-2004	24-May-2024	STERILIZATION OF DISPERSIONS OF NANOPARTICULATE ACTIVE AGENTS WITH GAMMA RADIATION
03.0109.		PCT	Japan		2006-532906		24-May-2004	24-May-2024	STERILIZATION OF DISPERSIONS OF NANOPARTICULATE ACTIVE AGENTS WITH GAMMA RADIATION
03.0110.		PCT	Canada		2533163	2533163	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110.		PCT	EPC	EP 1 658 053	4786037.4	1658053	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110.		PCT	France	EP 1 658 053	4786037.4	EP 1 658 053	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110.		PCT	Germany	6.02004E+11	4786037.4	DE 60 2004 012 117 T	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110.		PCT	Ireland	EP 1 658 053	4786037.4	EP 1 658 053	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110.		PCT	Italy	24217BE/2008	4786037.4	EP 1 658 053	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110.		PCT	Japan		2006-521069	2006-528176	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110.		PCT	Spain	2302035	4786037.4	EP 1 658 053	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0110.		PCT	United Kingdom	EP 1 658 053	4786037.4	EP 1 658 053	23-Jul-2004	23-Jul-2024	NOVEL COMPOSITIONS OF SILDENAFIL FREE BASE
03.0111.		PCT	Belgium	EP 1 651 189	EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111.		PCT	Canada		2534924		26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111.		PCT	EPC		4776615.9	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111.		PCT	France	EP 1 651 189	EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111.		PCT	Germany	EP 1 651 189	EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111.		PCT	Hungary	E005149	EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111.		PCT	Ireland	EP 1 651 189	EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111.		PCT	Italy	EP 1 651 189	EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111.		PCT	Japan		2006-523181		26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111.		PCT	Liechtenstein	EP 1 651 189	EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0111.	PCT	Spain	ES 2318330 T3	EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111.	PCT	Switzerland	EP 1 651 189	EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0111.	PCT	United Kingdom	EP 1 651 189	EP Validation	EP 1 651 189	26-Jul-2004	26-Jul-2024	NANOPARTICULATE METAXALONE COMPOSITIONS
03.0112.	PCT	Canada		2544404		31-Oct-2003	31-Oct-2023	NANOPARTICULATE NIMESULIDE COMPOSITIONS
03.0112.	PCT	Japan		2005-510942		31-Oct-2003	31-Oct-2023	NANOPARTICULATE NIMESULIDE COMPOSITIONS
03.0121.	PCT	Belgium		EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.	PCT	Canada		2544627		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.	PCT	EPC		4810201.6		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.	PCT	France		EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.	PCT	Germany		EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.	PCT	Hungary		EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.	PCT	Ireland		EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.	PCT	Italy		EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.	PCT	Japan		2006-539589		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.	PCT	Liechtenstein		EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.	PCT	Spain		EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.	PCT	Switzerland		EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0121.	PCT	United Kingdom		EP Validation		02-Nov-2004	02-Nov-2024	NANOPARTICULATE ACTIVE AGENT COMPOSITIONS HAVING A PEPTIDE SURFACE STABILIZER
03.0122.	PCT	Canada		2545856		09-Nov-2004	09-Nov-2024	COMPOSITIONS COMPRISING ANTIBODIES AND METHODS OF USING THE SAME FOR TARGETED NANOPARTICULATE ACTIVE AGENT DELIVERY
03.0122.	PCT	EPC		4810555.5	EP 1 689 442	09-Nov-2004	09-Nov-2024	COMPOSITIONS COMPRISING ANTIBODIES AND METHODS OF USING THE SAME FOR TARGETING NANOPARTICULATE ACTIVE AGENT DELIVERY
03.0122.	DIV	EPC		11172198.1		30-Jun-2011	09-Nov-2024	COMPOSITIONS COMPRISING ANTIBODIES AND METHODS OF USING THE SAME FOR TARGETING NANOPARTICULATE ACTIVE AGENT DELIVERY
03.0122.	PCT	Japan		2006-539722		09-Nov-2004	09-Nov-2024	COMPOSITIONS COMPRISING ANTIBODIES AND METHODS OF USING THE SAME FOR TARGETING NANOPARTICULATE ACTIVE AGENT DELIVERY

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0123.		PCT	Australia		2005307797		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123.		PCT	Brazil		P10518187-9		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123.		PCT	Canada		2587710		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123.		PCT	China (People's Republic)		2005-00046619.5	CN101106972A	16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123.		PCT	EPC		5851701.2		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123.		ORD	Hong Kong		8102504.7		26-Nov-2005	16-Nov-2025	INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS
03.0123.		PCT	Japan		2007-541454		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123.		PCT	Korea, Republic of		2007-7013288		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123.		PCT	Mexico		MX/A/2007/005885		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123.		PCT	Norway		20073065		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123.		PCT	Singapore	132306	200703464-8		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0123.		PCT	South Africa		2007/03919		16-Nov-2005	16-Nov-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE OLANZAPINE
03.0124.		PCT	Australia		2005311731		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	Brazil		P10518772-9		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	Canada		2589824		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	China (People's Republic)		2005800475	101365449	02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	Egypt		PCT/NA/524/2007		31-May-2007	31-May-2027	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	EPC		5852820.9		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	Eurasian Patent Organization		200701202		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		ORD	Hong Kong		8102505.6		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	India		2154/KOLNP/2007		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	Indonesia		W00200701693		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	Israel		183549		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	Japan		2007-544559		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	Korea, Republic of		2007-7014836		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	Mexico	278727	MX/A/2007006559		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	New Zealand	556009	556009		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	Norway		20073334		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	Singapore	132897	200704011-6		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	South Africa	200704528	2007/04528		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0124.		PCT	Ukraine	89513	200707397		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0124.		PCT	United Arab Emirates		473/2007		02-Dec-2005	02-Dec-2025	NANOPARTICULATE BENZOTHIOPHENE FORMULATIONS
03.0125.		PCT	Canada		2631757		04-Dec-2006		NOVEL MOMETASONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
03.0125.		PCT	EPC		6844719.2		04-Dec-2006		NOVEL MOMETASONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
03.0125.		PCT	Japan		2008-543494		04-Dec-2006	04-Dec-2026	NOVEL MOMETASONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
03.0132.		PCT	Canada		2601363		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132.		PCT	China (People's Republic)		200680017268.X		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132.		PCT	EPC		6748432.9		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132.		ORD	Hong Kong		8106808.1		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132.		PCT	Israel		185953		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132.		PCT	Mexico		MX/A/2007/011495		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132.		PCT	New Zealand		561666		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132.		PCT	Nigeria		NG/C/2008/718		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132.		PCT	Norway		20075294		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132.		PCT	Singapore		200708549-1		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132.		PCT	South Africa		2007/08457		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0132.		PCT	United Arab Emirates		857/2007		17-Mar-2006	17-Mar-2026	NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
03.0133.		PCT	EPC		6738842.1		16-Mar-2006	16-Mar-2026	NANOPARTICULATE LEUKOTRIENE RECEPTOR ANTAGONIST/CORTICOSTEROID FORMULATIONS
03.0134.		PCT	Australia		2006227623		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134.		PCT	Brazil		P10606282-2		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134.		PCT	Canada		2601312		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134.		PCT	EPC		6738555.9		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134.		ORD	Hong Kong		81070754	1116430	16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134.		PCT	Israel		185952		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134.		PCT	Japan		2008-502039		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134.		PCT	Korea, Republic of		2007-7023749		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134.		PCT	Mexico		MX/A/2007/011494		17-Sep-2007	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134.		PCT	Norway		20075295		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS
03.0134.		PCT	South Africa		2007/08458		16-Mar-2006	16-Mar-2026	INJECTABLE COMPOSITIONS OF NANOPARTICULATE IMMUNOSUPPRESSIVE COMPOUNDS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0135.		PCT	Australia		2006226887		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135.		PCT	Brazil		P10609700-6		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135.		PCT	Canada		2602341		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135.		PCT	EPC		6739359.5		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135.		PCT	Eurasian Patent Organization		200702049		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135.		PCX	Hong Kong		8107065.7		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135.		PCT	Israel		186159		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135.		PCT	Japan		2008-503175	2008-534509	23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135.		PCT	Korea, Republic of		2007-7024129		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135.		PCT	Mexico		MX/a/2007/011772		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135.		PCT	Norway		20075398		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135.		PCT	Singapore	135679	200708475-9		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0135.		PCT	South Africa	2007/08544	2007/08544		23-Mar-2006	23-Mar-2026	NANOPARTICULATE CORTICOSTEROID AND ANTIHISTAMINE FORMULATIONS
03.0137.		PCT	Australia		2006235487		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137.		PCT	Brazil		P10607537-1		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137.		PCT	Canada		2604735	2604735	12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137.		PCT	China (People's Republic)		200680021016.4		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137.		PCT	EPC		6740896.3	EP 1 871 345	12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137.		PCT	Eurasian Patent Organization	14611	200702214		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137.		PCX	Hong Kong		8107271.7		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137.		PCT	India		3956/KOLNP/2007		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137.		PCT	Israel		186609		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0137.		PCT	Japan		2008-506632		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137.		PCT	Korea, Republic of		2007-7025983		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137.		PCT	Mexico		MX/A/2007/012778		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137.		PCT	Norway		20075774		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137.		PCT	Singapore	136501	200716779-4		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0137.		PCT	South Africa	2007/08702	2007/08702		12-Apr-2006	12-Apr-2026	NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS
03.0147.		PCT	South Africa	2007/10113	2007/10113		09-May-2006	09-May-2026	NANOPARTICULATE CLOPIDOGREL FORMULATIONS
03.0151.		PCT	Canada		2680106		04-Sep-2009	20-Mar-2028	GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHOD OF MAKING SAME
03.0151.		PCT	EPC		8732593.2	EP 2 139 470	20-Oct-2009	20-Mar-2028	GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHOD OF MAKING SAME
03.0151.		PCX	Hong Kong		10106443.8		02-Jul-2010	20-Mar-2028	GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHOD OF MAKING SAME
03.0151.		PCT	Japan		2009-554749	2010-522207	18-Sep-2009	20-Mar-2028	GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHOD OF MAKING SAME
03.0151.		ORD	PCT		PCT/US2008/057701	WO/2008/118754 A3	20-Mar-2008		GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHOD OF MAKING SAME
03.0152.		PCT	Australia		2007221471		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152.		ORD	Brazil		PI0708343-2		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152.		PCT	Canada		2643492		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152.		PCT	China (People's Republic)		200780013936.6		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152.		PCT	EPC		7750325.8		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152.		PCX	Hong Kong		9110368.4	1132903A	06-Nov-2009	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152.		PCT	India		3475/KOLNP/2008		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152.		PCT	Israel		193692		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152.		PCT	Japan		2008-557272		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152.		PCT	Korea, Republic of			WO/2007/100466	09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152.		PCT	Mexico			WO/2007/100466	09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152.		PCT	New Zealand		570876		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152.		PCT	Singapore		747469		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0152.		PCT	South Africa	2008/07397	2008/07397		09-Feb-2007	09-Feb-2027	NANOPARTICULATE CARVEDILOL FORMULATIONS
03.0153.		PCT	Australia		2007210190		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0153.		PCT	Brazil		PI0707314-3		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153.		PCT	Canada		2640444		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153.		PCT	China (People's Republic)		200780010847.6	101443018	24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153.		PCT	EPC		7716966.2		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153.		PCX	Hong Kong		9110975.9	1133182A	24-Nov-2009	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153.		PCT	Israel		193079		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153.		PCT	Japan		2008-552375		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153.		PCT	Korea, Republic of		2008-7020792		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153.		PCT	Mexico		MX/A/2008/009725		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153.		PCT	New Zealand		570604		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153.		PCT	Singapore	144645	496763		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0153.		PCT	South Africa	2008/06758	2008/06758		24-Jan-2007	24-Jan-2027	STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS
03.0154.		PCT	Armenia	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Australia		2005316473		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Azerbaijan	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Belarus	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Brazil		PI0519088-6		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Canada		2590675		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	China (People's Republic)		200580047894.9		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	EPC		5854300	EP 1 835 889	15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Eurasian Patent Organization	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCX	Hong Kong		8103316.3		25-Mar-2008	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	India		2407/KOLNP/2007		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Israel		183945		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Japan		2007-546924		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Kazakhstan	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Korea, Republic of		2007-7015992		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Kyrgyz Republic	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Mexico		MX/A/2007/007342		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Moldova	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Norway		20073559		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0154.		PCT	Russian Federation	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.	2	DIV	Singapore		334624	161203	12-Mar-2010	15-Dec-2025	INJECTABLE FORMULATIONS OF NANOPARTICULATE TACROLIMUS
03.0154.		PCT	South Africa		2007-05213		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Tajikistan	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0154.		PCT	Turkmenistan	13741	200701274		15-Dec-2005	15-Dec-2025	NANOPARTICULATE TACROLIMUS FORMULATIONS
03.0156.		PCT	Australia		2006216640		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0156.		PCT	Brazil		PI0608173-8		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0156.		PCT	Canada		2598441		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0156.		PCT	China (People's Republic)		200680012670.9	CN 101160118A	16-Oct-2007	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0156.		PCT	EPC		6735983.6		17-Sep-2007	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0156.		PCT	Eurasian Patent Organization		200701793		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0156.		PCX	Hong Kong		8104955.7		08-Oct-2008	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0156.		PCT	Israel		185292		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0156.		PCT	Japan		2007-557184		24-Aug-2007	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0156.		ORD	Korea, Republic of		7021919/2007		21-Sep-2007	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0156.		PCT	Mexico		MX/a/2007/010394		24-Aug-2007	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0156.		PCT	Norway		20074859		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0156.		PCT	Singapore		200706247-4		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0156.		PCT	South Africa	2007/06783	2007/06783		24-Feb-2006	24-Feb-2026	NANOPARTICULATE FORMULATIONS OF DOCETAXEL AND ANALOGUES THEREOF
03.0157.		PCT	Armenia	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Australia		2006214443		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		DIV	Australia		tbz		tbz		AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Azerbaijan	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Belarus	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0157.		PCT	Brazil		PI0608087-1		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Canada		2597716		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	China (People's Republic)		200680012468.6		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	EPC		6735067.8		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.	2	DIV	EPC		11001512		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE (CLOBAZAM)
03.0157.	DIV2	DIV	EPC		11001511		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE (CLONAZEPAM AND MIDAZOLAM)
03.0157.		PCT	Eurasian Patent Organization	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		ORD	Hong Kong		8105286.4		15-Feb-2006		AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Israel		185265		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Japan		2007-555348		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Kazakhstan	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Korea, Republic of		2007-7020820		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Kyrgyz Republic	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Mexico		MX/A/2007009915		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Moldova	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Norway		20074602		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Russian Federation	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Singapore		200705897-7		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	South Africa	2007/07610	2007/07610		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Tajikistan	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0157.		PCT	Turkmenistan	13433	200701731		15-Feb-2006	15-Feb-2026	AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
03.0167.		PCT	Armenia		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0167.		PCT	Australia		2006309295		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Azerbaijan		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Belarus		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Canada		2610480	2610480	05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	China (People's Republic)		200680028319		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	EPC		6844132.8	EP 1 901 728	05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Eurasian Patent Organization		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Israel		187842		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Japan		2008-514948		05-Jun-2006	01-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Kazakhstan		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Korea, Republic of		2007-7030960		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Kyrgyz Republic		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Mexico		MX/A/2007/015304		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Moldova		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Norway		200706692		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Russian Federation		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Singapore	137986	200718248-8		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	South Africa	2007/10764	2007/10764		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Tajikistan		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0167.		PCT	Turkmenistan		200702638		05-Jun-2006	05-Jun-2026	NANOPARTICULATE ACETAMINOPHEN COMPOSITIONS
03.0168.		PCT	Australia		2006255177		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		PCT	Austria		6772091.2		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		EPC	Belgium	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		PCT	Canada		2610448	2610448	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		PCT	China (People's Republic)		2006-80028329.2	101232870	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		PCT	EPC	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		PCT	Eurasian Patent Organization		200702641		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.	2	DIV	Eurasian Patent Organization		201100022		13-Jan-2011	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		EPC	France	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		EPC	Germany	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		PCX	Hong Kong	HK1118467	8110052.6	1118467	10-Sep-2008	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0168.		EPC	Hungary	EP 1 895 984	6772091.2	1895984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		EPC	Ireland	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		PCT	Israel		187841		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		EPC	Italy	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		PCT	Japan		2008-514949		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		PCT	Korea, Republic of		2007-703987		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		EPC	Liechtenstein		6772091.2		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		PCT	Mexico	270484	MX/A/2007/015309		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		PCT	Norway		20076691		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		PCT	Singapore	137987	2007/182496		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		PCT	South Africa	2007/10763	2007/10763		05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		EPC	Spain	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		EPC	Switzerland	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0168.		EPC	United Kingdom	EP 1 895 984	6772091.2	EP 1 895 984	05-Jun-2006	05-Jun-2026	NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS
03.0169.		EPC	Belgium	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0169.		ORD	Canada		2611475	2611475	08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0169.		PCT	EPC	EP 1 898 882	6772583.8	EP 1 898 882	08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0169.		EPC	France	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0169.		EPC	Germany	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0169.		EPC	Hungary	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0169.		EPC	Ireland	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0169.		EPC	Italy	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0169.		PCT	Japan		2006-50702540713		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0169.		EPC	Liechtenstein	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0169.		EPC	Spain	EP 1 898 882	6772583.8	2335608	08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0169.		EPC	Switzerland	EP 1 898 882	EP Validation		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0169.		EPC	United Kingdom	EP 1 898 882	6772583.8		08-Jun-2006	08-Jun-2026	NANOPARTICULATE EBASTINE FORMULATIONS
03.0171.		PCT	Japan		2008-517090		14-Jun-2006	14-Jun-2026	NANOPARTICULATE AZELINIDIPINE FORMULATIONS
03.0172.		ORD	Argentina		70102341	63940	30-May-2007	30-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.		ORD	Australia		2007256983		12-Jan-2009	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.0172.		ORD	Canada		2653504		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.		ORD	EPC		7784042.9	EP 2 040 675	22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.		ORD	Iran (Islamic Republic of)	38603143	38603143		28-May-2007	28-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.		ORD	Israel		195524		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.		ORD	Japan		2009-513380		22-May-2007	30-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.		ORD	Korea, Republic of		2008-7031649		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.		ORD	Mexico		MX/A/2008015275		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.		ORD	New Zealand		573555		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.		ORD	Pakistan		606/2007		26-May-2007	26-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.		ORD	Singapore		200808543.3		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.	2	DIV	Singapore		20101417.2		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.		ORD	South Africa	2008/09971	2008/09971		22-May-2007	22-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.		ORD	Taiwan		96119120		29-May-2007	29-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0172.		ORD	Venezuela		01148-2007		30-May-2007	30-May-2027	NANOPARTICULATE POSACONAZOLE FORMULATIONS
03.0174.		ORD	Canada		2614412		06-Jul-2006	06-Jul-2026	NANOPARTICULATE CLARITHROMYCIN FORMULATIONS
03.0174.		ORD	Canada		2008-519732		06-Jul-2006	06-Jul-2026	NANOPARTICULATE CLARITHROMYCIN FORMULATIONS
03.0176.		PCT	Japan		2622200		11-Mar-2008	13-Sep-2026	NANOPARTICULATE TADALAFIL FORMULATIONS
03.0176.		PCT	EPC		6803492.5		13-Sep-2006	13-Sep-2026	NANOPARTICULATE TADALAFIL FORMULATIONS
03.0176.		PCT	Japan		2008-531268		13-Sep-2006	13-Sep-2026	NANOPARTICULATE TADALAFIL FORMULATIONS
03.0177.		PCT	Canada		2622758		13-Sep-2006	13-Sep-2026	INJECTABLE FORMULATIONS OF NANOPARTICULATE ARIPIIPRAZOLE
03.0177.		PCT	EPC		6814574.7		13-Sep-2006	13-Sep-2026	INJECTABLE FORMULATIONS OF NANOPARTICULATE ARIPIIPRAZOLE
03.0177.	2	DIV	EPC		10012426.2	EP 2 279 727	30-Sep-2010	13-Sep-2026	INJECTABLE FORMULATIONS OF NANOPARTICULATE ARIPIIPRAZOLE
03.0177.		PCT	Japan		2008-531269		13-Sep-2006	13-Sep-2026	INJECTABLE FORMULATIONS OF NANOPARTICULATE ARIPIIPRAZOLE
03.0178.		ORD	Australia		2007257667		12-Jun-2007	12-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
03.0178.		ORD	Canada		2654909		12-Jun-2007	12-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
03.0178.		ORD	EPC		7798449		12-Jan-2009	12-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
03.0178.		ORD	Japan		2009-515607		12-Jun-2007	12-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
03.0178.		ORD	Korea, Republic of		2009-7000297	09-18864	07-Jan-2009	12-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
03.0178.		ORD	Taiwan		96121317		13-Jun-2007	13-Jun-2027	NANOPARTICULATE KINASE INHIBITOR FORMULATIONS
03.0180.		PCT	Canada		2657379		09-Jan-2009	09-Jul-2027	NANOPARTICULATE FORMULATIONS OF SORAFENIB TOSYLATE
03.0180.		PCT	EPC		7799418.4		10-Feb-2009	09-Jul-2027	NANOPARTICULATE FORMULATIONS OF SORAFENIB TOSYLATE
03.0180.		PCT	Japan		2009-519619		09-Jan-2009	09-Jul-2027	NANOPARTICULATE FORMULATIONS OF SORAFENIB TOSYLATE
03.2004.		ORD	Argentina		P050102026		17-May-2005	17-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004.		ORD	China (People's Republic)		2005-80023796.1	Published	17-May-2005	17-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
03.2004.		ORD	EPC		5779926.4	EP 1 773 335	17-May-2005	17-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004.		ORD	Hong Kong		9109680.7		17-May-2005	17-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004.		ORD	India		06658/DELNP/2006		17-May-2005	17-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004.		ORD	Japan		2007-527369	2008-505982	17-May-2005	17-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004.		ORD	Malaysia		PI20052114		11-May-2005	11-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004.		ORD	Malta		2778		18-May-2005	18-May-2025	NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2004.		ORD	Norway		20065737		17-May-2005		NANOPARTICULATE DISPERSION CONTAINING LACTAM COMPOUND
03.2007.		PCT	EPC		8859115.1	EP 2 230 906	03-Jun-2010		NANOPARTICULATE ANIDULAFUNGIN COMPOSITIONS AND METHODS FOR MAKING THE SAME
03.2007.		ORD	PCT		PCT/US2008/086642	WO/2009/076620	12-Dec-2008		NANOPARTICULATE ANIDULAFUNGIN COMPOSITIONS AND METHODS FOR MAKING THE SAME
03.2013.		ORD	PCT		PCT/US2010/036304	WO/2010/138661	27-May-2010	27-May-2014	NANOPARTICULATE ANTICANCER COMPOSITIONS AND METHODS FOR MAKING THE SAME
03.2021.		ORD	Canada		2723998		10-Nov-2010		COMBINATION OF A TRIPTAN AND AN NSAID
03.2021.		PCT	EPC		9763482.8		07-Jan-2011		COMBINATION OF A TRIPTAN AND AN NSAID
03.2021.		ORD	Japan		2011-513648		10-Dec-2010		COMBINATION OF A TRIPTAN AND AN NSAID
03.2021.		ORD	PCT		PCT/US2009/048808	WO/2009/152192	10-Jun-2009		COMBINATION OF A TRIPTAN AND AN NSAID
03.2033.		PCT	PCT		PCT/US2011/036949		18-May-2011	18/05/2015	NANOPARTICULATE CINACALCET COMPOSITIONS CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
04.1007.		ORD	Canada		2627948		26-Oct-2006	26-Oct-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
04.1007.	2	ORD	Canada		2627951		26-Oct-2006	26-Oct-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
04.1007.		ORD	EPC		6826636	EP 1 948 135	26-Oct-2006	26-Oct-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
04.1007.	2	ORD	EPC		6826637.8	EP 1 951 210	26-Oct-2006	26-Oct-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRAZINE HYDROCHLORIDE
04.1008.		PCT	Australia		2006209212		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.		PCT	Brazil		PI0606932-0		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.		PCT	Canada		2595885		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1008.		PCT	EPC		6719564.4		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.		PCT	Eurasian Patent Organization		200701591		24-Aug-2007	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.		PCX	Hong Kong		8104561.3		24-Apr-2008	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.		PCT	India		3009/KOLNP/2007		17-Aug-2007	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.		PCT	Israel		1848768		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.		PCT	Japan		2007-553223	2008-528607	26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.		PCT	Mexico		MX/a/2007/008985		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.		PCT	Norway		20074313		23-Aug-2007	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.		PCT	Singapore	134450	2007/05445-5		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1008.		PCT	South Africa	2007/06068	2007/06068		26-Jan-2006	26-Jan-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENT
04.1012.		PCT	Australia		2006235483		12-Apr-2006	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.		PCT	Canada		2602268		25-Sep-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.		PCT	China (People's Republic)		200680016448.6		13-Nov-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.		PCT	EPC		6749871.7	EP 1 868 583	12-Apr-2006	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.		PCX	Hong Kong		8100061.6		12-Apr-2006	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.		PCT	Israel		186471		02-Oct-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.		PCT	Japan		2008-506630	2008-535922	12-Oct-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.		PCT	Korea, Republic of		7026254/2007		12-Nov-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1012.		PCT	Mexico		MX/ai/2007/012763		12-Oct-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.		PCT	Norway		20075715		08-Nov-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.		PCT	Singapore		200716821-4		11-Oct-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1012.		PCT	South Africa	2007/08213	2007/08213		26-Sep-2007	12-Apr-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN FOR THE TREATMENT OF A BACTERIAL INFECTION
04.1013.		PCT	Canada		2604192		11-Oct-2007	12-Apr-2026	MODIFIED RELEASE COMPOSITIONS COMPRISING A FLUOROCYTIDINE DERIVATIVE FOR THE TREATMENT OF CANCER
04.1013.		PCT	EPC		6749864.2		12-Nov-2007	12-Apr-2026	MODIFIED RELEASE COMPOSITIONS COMPRISING A FLUOROCYTIDINE DERIVATIVE FOR THE TREATMENT OF CANCER
04.1013.		PCT	Germany		112006000873		12-Apr-2006	12-Apr-2026	MODIFIED RELEASE COMPOSITIONS COMPRISING A FLUOROCYTIDINE DERIVATIVE FOR THE TREATMENT OF CANCER
04.1013.		PCT	Japan		2008-506628	2008-535920	12-Apr-2006	12-Apr-2026	MODIFIED RELEASE COMPOSITIONS COMPRISING A FLUOROCYTIDINE DERIVATIVE FOR THE TREATMENT OF CANCER
04.1060.		ORD	Austria	EP 0 859 959	96938439.5	E246808	11-Nov-1996	11-Nov-2016	PEPTIDES WHICH ENHANCE TRANSPORT ACROSS TISSUES AND METHODS OF IDENTIFYING AND USING
04.1060.		ORD	Belgium	EP 0 859 959	96938439.5		11-Nov-1996	11-Nov-2016	PEPTIDES WHICH ENHANCE TRANSPORT ACROSS TISSUES AND METHODS OF IDENTIFYING AND USING
04.1060.		ORD	Finland	EP 0 859 959	96938439.5		11-Nov-1996	11-Nov-2016	PEPTIDES WHICH ENHANCE TRANSPORT ACROSS TISSUES AND METHODS OF IDENTIFYING AND USING
04.1060.		ORD	Greece	EP 0 859 959	96938439.5		11-Nov-1996	11-Nov-2016	PEPTIDES WHICH ENHANCE TRANSPORT ACROSS TISSUES AND METHODS OF IDENTIFYING AND USING
04.1060.		ORD	Luxembourg	EP 0 859 959	96938439.5		11-Nov-1996	11-Nov-2016	PEPTIDES WHICH ENHANCE TRANSPORT ACROSS TISSUES AND METHODS OF IDENTIFYING AND USING
04.1060.		ORD	Monaco	EP 0 859 959	96938439.5		11-Nov-1996	11-Nov-2016	PEPTIDES WHICH ENHANCE TRANSPORT ACROSS TISSUES AND METHODS OF IDENTIFYING AND USING
04.1060.		ORD	Netherlands	EP 0 859 959	96938439.5		11-Nov-1996	11-Nov-2016	PEPTIDES WHICH ENHANCE TRANSPORT ACROSS TISSUES AND METHODS OF IDENTIFYING AND USING
04.1060.		ORD	Portugal	EP 0 859 959	96938439.5		11-Nov-1996	11-Nov-2016	PEPTIDES WHICH ENHANCE TRANSPORT ACROSS TISSUES AND METHODS OF IDENTIFYING AND USING
04.1060.		ORD	Sweden	EP 0 859 959	96938439.5		11-Nov-1996	11-Nov-2016	PEPTIDES WHICH ENHANCE TRANSPORT ACROSS TISSUES AND METHODS OF IDENTIFYING AND USING

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1064.		ORD	Belgium	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.		ORD	Cyprus, Republic of	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.		ORD	EPC	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.		ORD	France	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.		ORD	Germany	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.		ORD	Ireland	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.		ORD	Italy	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.		ORD	Liechtenstein	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.		ORD	Luxembourg	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.		ORD	Monaco	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.		ORD	Switzerland	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1064.		ORD	United Kingdom	EP 1 131 344	99972640.9		19-Nov-1999	19-Nov-2019	RETRO-INVERSION PEPTIDES THAT TARGET GASTRO-INTESTINAL TRACT TRANSPORT RECEPTORS AND USE THEREOF
04.1065.		PCT	Canada	2386231	2386231		27-Sep-2000	27-Sep-2020	MEMBRANE TRANSLOCATING PEPTIDE DRUG DELIVERY SYSTEM
04.1068M.		PCT	EPC		3726420.7	EP 1 575 987	21-Apr-2003	21-Apr-2023	CONJUGATES OF MEMBRANE TRANSLOCATING AGENTS AND PHARMACEUTICALLY ACTIVE AGENTS\$CONJUGUES D'AGENTS DE TRANSLOCATION MEM
04.1103. 04.1255.		PCT	Japan United States		2008-551241 08/479,509	2009-514989	09-Nov-2007	09-May-2026 2-Apr-2016	MODIFIED RELEASE LOXOPROFEN COMPOSITIONS OR BIODEGRADABLE MICRO- AND NANOSPHERES CONTAINING

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1806.		ORD	Australia	657706	86961/91		01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		EPC	Austria	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		EPC	Belgium	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		ORD	Canada	2054822	2054822	2054822	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		EPC	Denmark	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		ORD	EPC	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		EPC	France	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		EPC	Germany	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		EPC	Greece	20000400471	3032769	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		ORD	Ireland	82916	3952/90		01-Nov-1991	02-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		EPC	Italy	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		EPC	Luxembourg	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		EPC	Netherlands	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		ORD	New Zealand	240439	240439		01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		ORD	South Africa	91/8711	91/8711		01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		EPC	Spain	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		EPC	Sweden	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		EPC	Switzerland	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1806.		EPC	United Kingdom	EP 0 484 186	91310143.2	EP 0 484 186	01-Nov-1991	01-Nov-2011	PREPARATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
04.1807.			Finland	EP 0 612 258	92923044.9			10-Nov-2012	Passive transdermal device
04.1807.		EPC	Germany	EP 0 612 258	92923044.9		05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Austria	E239454	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Belgium	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Denmark	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		PCT	EPC	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1809.		EPC	Finland	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	France	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Germany	69721845.7	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Greece	3045183	20030402960	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Ireland	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Italy	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		PCT	Japan	4535613	2000-516654		05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Liechtenstein	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Luxembourg	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Monaco	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Netherlands	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Portugal	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		ORD	South Africa	98/9463	98/9463	EP 1 023 051	16-Oct-1998	16-Oct-2018	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Spain	ES2199378T3	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Sweden	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	Switzerland	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		ORD	Taiwan	172439	87117680	520298	26-Oct-1998	26-Oct-2018	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809.		EPC	United Kingdom	EP 1 023 051	97947848.4	EP 1 023 051	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809K.	2	PCT	Canada	2306333	2306333	2306333	05-Dec-1997	05-Dec-2017	ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1809K.		DIV	Canada		2558783		21-Sep-2006		ORAL MORPHINE MULTIPARTICULATE FORMULATION
04.1816E.	DIV2	DIV	Australia	2005247019	2005247019		22-Dec-2005	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816E.	DIV3	DIV	Australia	2007203497	2007203497		26-Jul-2007	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816E.	DIV4	DIV	Australia		2009201786		05-May-2009	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816E.		PCT	Austria	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Belgium	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Canada	2348871	2348871	2348871	01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.	DIV	DIV	Canada		2653839		04-Feb-2009	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Cyprus, Republic of	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Denmark	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	EPC	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.	2	DIV	EPC		8013053.7	EP 1 126 826 EP 2 020 229	01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.	3	DIV	EPC		10182522.2		29-Sep-2010	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Finland	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	France	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Germany	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Greece	3067580	99956822.3	EP 1 126 826	01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Ireland	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.	DIV2	DIV	Israel		211075		03-Feb-2011	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816E.		PCT	Italy	EP 1 126 826	19153BE/2009		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Japan	4613275	2000-579194		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1816E.	2	DIV	Japan		2010-156897		09-Jul-2010	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Liechtenstein	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Luxembourg	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Monaco	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Netherlands	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Portugal	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Spain	EP 1 126 826	ES 2313797 T3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Sweden	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	Switzerland	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816E.		PCT	United Kingdom	EP 1 126 826	99956822.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION
04.1816N.		ORD	Argentina		P990105538		02-Nov-1999	02-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Australia	770645	13350/00		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.	D	DIV	Australia	2004202078	AU 2004202078 B2		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Brazil		PI 9914977-0		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		ORD	Chile		2491-99		02-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	China (People's Republic)	ZL99814002.3	99814002.3		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		ORD	Colombia		990699009		02-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Czech Republic		PV2001-1539		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		ORD	Hong Kong		30102681.7		14-Apr-2003	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Hungary		P0104039		02-Nov-1999	02-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Indonesia	100018066	W-200101174		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Israel	142896	142896		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.	D	DIV	Israel		179379		16-Nov-2006	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Korea, Republic of	812832	7005518/2001		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		ORD	Malaysia	MY122159A	PI 99004713		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Mexico	238634	1004381		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.	2	DIV	Mexico		67878		10-Jul-2006	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1816N.		PCT	New Zealand	511442	511442		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Norway		2001-2139		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		ORD	Pakistan	137141	0918/99		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		ORD	Peru	3680	1106.99		03-Nov-1999	03-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		ORD	Philippines	1999/02721	1-1999-02721		29-Oct-1999	29-Oct-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Poland	NR 205109	P348633		01-Nov-1999	01-Nov-1999	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Russian Federation	2236847	2001111887		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Singapore	80486	200102450-4		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Slovakia		PV2001-599		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.	2	DIV	Slovakia		PV 5011-2011		02-Mar-2011	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		ORD	Taiwan	I 292717	88119049		02-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.	D	DIV	Taiwan	I 319327	95111114	200630120	31-Mar-2006	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		ORD	Thailand	53705	9901004094		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Turkey	2001 01216B	01/1216		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		ORD	Venezuela		1999-002232		02-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1816N.		PCT	Viet Nam	5916	1-2001-00390		01-Nov-1999	01-Nov-2019	MULTIPARTICULATE MODIFIED RELEASE COMPOSITION (METHYLPHENIDATE)
04.1819.		PCT	Czech Republic		PV2001-4618		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.		PCT	EPC	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.		EPP	Hungary		P0201884		10-May-2000		MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.		ORD	Ireland	83094	990406		20-May-1999	20-May-2019	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1819JZ.		PCT	Austria	E367153T1	925548		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819JZ.		EPP	Belgium	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819JZ.		EPP	Cyprus, Republic of	EP 1 178 780	925548		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819JZ.		EPP	Denmark	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819JZ.	2	DIV	EPC		7008264.9	EP 1 852 111 A1	23-Apr-2007	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819JZ.		EPP	Finland	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819JZ.		EPP	France	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819JZ.		EPP	Germany	60035579.9	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819JZ.		EPP	Greece	20070403016	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819JZ.	2	DIV	Ireland	EP 1 178 780	925548		20-May-1999	20-May-2019	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819JZ.		EPP	Italy	EP 1 178 780	925548		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819JZ.		EPP	Liechtenstein	EP 1 178 780	925548		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819JZ.		EPP	Luxembourg	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819JZ.		EPP	Monaco	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1819.JZ.		EPP	Netherlands	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ.		EPP	Portugal	EP 1 178 780	925548		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ.		EPP	Spain	2290027	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ.		EPP	Sweden	EP 1 178 780	925548		10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ.		EPP	Switzerland	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1819.JZ.		EPP	United Kingdom	EP 1 178 780	925548	EP 1 178 780	10-May-2000	10-May-2020	MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (FLUVOXAMINE)
04.1830.		PCT	Canada	2462737	2462737	2462737	09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM ...
04.1830.		PCT	EPC	EP 1 436 610	2779792.7	EP 1 436 610	09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM ...
04.1830.		EPP	France	EP 1 436 610	2779792.7		09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM ...
04.1830.		EPP	Germany	EP 1 436 610	2779792.7		09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM ...
04.1830.		EPP	Ireland	EP 1 436 610	2779792.7		09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM ...
04.1830.		EPP	Italy	EP 1 436 610	2779792.7		09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM ...
04.1830.		PCT	Japan	4521188	2003-536745		09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM ...
04.1830.		EPP	Spain	EP 1 436 610	2779792.7		09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM ...

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
04.1830.		EPP	United Kingdom	EP 1 436 610	2779792.7		09-Oct-2002	09-Oct-2022	APPARATUS AND METHOD FOR CONCURRENTLY MONITORING ACTIVE RELEASE AND PHYSICAL APPEARANCE OF SOLID DOSAGE FORM ...
04.1902.		PCT	Canada		2611938	2611938	09-Jun-2006	09-Jun-2026	MODIFIED RELEASE TICLOPIDINE COMPOSITIONS
04.1902.		PCT	EPC		6772777.6	EP 1 910 718	09-Jun-2006	09-Jun-2026	MODIFIED RELEASE TICLOPIDINE COMPOSITIONS
04.1902.		PCT	Japan		2008-516957		09-Jun-2006	09-Jun-2026	MODIFIED RELEASE TICLOPIDINE COMPOSITIONS
05.0082.US	2	ORD	USA	6908626	10/288,928	US 2003-0137067 A1	11-Oct-2002	25-Dec-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
05.0166.US	3	ORD	USA		12/407,684		19-Mar-2009	19-Mar-2029	COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
05.1010.US	2	ORD	USA		11/297,737	US 2006-0121112 A1	08-Dec-2005	08-Dec-2025	TOPIRAMATE PHARMACEUTICAL COMPOSITION
05.1014.US	2	ORD	USA		11/571,377		14-Jan-2008	02-Mar-2026	CONTROLLED RELEASE COMPOSITIONS COMPRISING HETEROCYCLIC AMIDE DERIVATIVE NANOPARTICLES
05.1015.US	2	ORD	USA		11/568,698		03-Nov-2006	13-Apr-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING PROSTAGLANDIN DERIVATIVES
05.1101.US	2	ORD	USA		11/569,206		16-Nov-2006	09-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN K2
05.1104.US	2	ORD	USA		11/568,825	US 2009-0269400 A1	11-May-2009	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANITIN)
05.1105.US	2	ORD	USA		11/568,835	US 2009-0297596 A1	23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
05.1256.US		ORD	USA	5641515	08/474,161		07-Jun-1995	07-Jun-2015	CONTROLLED RELEASE BIODEGRADABLE NANOPARTICLES CONTAINING INSULIN
05.1901.US	4	CON	USA		11/671,276		06-Feb-2007	06-Feb-2027	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CEFIDITOREN
05.1903.US	3	CON	USA		11/672,263	US 2011-0008435 A1	07-Feb-2007		NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
05.1904.US	2	CIP	USA		11/479,013	US 2010-0247636 A1	30-Jun-2006	30-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING NILVADIPINE
05.2026.US	2	ORD	USA		12/049,046	US 2008-0226734 A1	14-Mar-2008	14-Mar-2028	COMBINATION OF A NARCOTIC AND NON-NARCOTIC ANALGESIC
05.2025.US	2	CIP	USA		11/768,154	US 2008-0113025 A1	25-Jun-2007	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
05.2026.US	2	CIP	USA		11/768,169	US 2008-0102121 A1	25-Jun-2007	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.0082.		EPC	Austria	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Belgium	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Bulgaria	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		PCT	Canada		2463495	2463495	11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS
06.0082.		EPC	Cyprus, Republic of	EP 1 443 912	2800993.4	CY1107810	11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Czech Republic	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Denmark	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		PCT	EPC	EP 1 443 912	2800993.4	EP 1 443 912	11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS
06.0082.		EPC	Estonia	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Finland	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	France	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Germany	60222160.9	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Greece	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Ireland	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.0082.		EPC	Italy	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		PCT	Japan		2003-533905		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF CONTROLLED RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS
06.0082.	2	DIV	Japan		2009-242799	2010-47599	11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND IMMEDIATE RELEASE CHARACTERISTICS
06.0082.		EPC	Luxembourg	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Monaco	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Netherlands	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Portugal	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Slovakia	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Spain	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Sweden	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Switzerland	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	Turkey	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0082.		EPC	United Kingdom	EP 1 443 912	2800993.4		11-Oct-2002	11-Oct-2022	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS
06.0166.		ORD	Australia		2009225719		03-Aug-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166.		ORD	Canada		2715422		11-Aug-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.0166.	ORD	EPC		9721726.9	EP 2 268 265	20-Oct-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166.	ORD	Israel		208176		15-Sep-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166.	ORD	Japan		2011-500895		17-Sep-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166.	ORD	Korea, Republic of		7019413/2010		31-Aug-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166.	ORD	Mexico		MX/a/2010/009848		07-Sep-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166.	ORD	Norway		20101468		19-Oct-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166.	ORD	PCT		PCT/US2009/037379		17-Mar-2009		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166.	ORD	Singapore		1981108		27-Aug-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166.	ORD	South Africa		2010/05530		03-Aug-2010		COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.0166.	ORD	Taiwan		98109234		20-Mar-2009	20-Mar-2029	COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB MESYLATE AND METHODS OF USE
06.1014.	PCT	Canada		2598288		02-Mar-2006	02-Mar-2026	NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
06.1014.	PCT	EPC		6736732.6		02-Mar-2006	02-Mar-2026	NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
06.1014.	PCX	Hong Kong		8105661.9		21-May-2008	02-Mar-2026	NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
06.1014.	PCT	Japan		2007-558231		02-Mar-2006	02-Mar-2026	NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
06.1014.	2 DIV	Japan		2009-045169		27-Feb-2009	02-Mar-2026	NANOPARTICULATE COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
06.1015.	PCT	Canada		2604281	2604281	11-Oct-2007	13-Apr-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING PROSTAGLANDIN DERIVATIVES
06.1015.	PCT	EPC		6749978		12-Nov-2007	13-Apr-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING PROSTAGLANDIN DERIVATIVES
06.1015.	ORD	Hong Kong		8110293.5		13-Apr-2006	13-Apr-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING PROSTAGLANDIN DERIVATIVES
06.1015.	PCT	Japan		2008-506672		13-Apr-2006	13-Apr-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING PROSTAGLANDIN DERIVATIVES
06.1101.	PCT	Japan		2008-511296		09-Nov-2007	09-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN K2

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.1104.		PCT	Australia		2006344711		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.		PCT	Canada		2609296	2609296	16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.		PCT	China (People's Republic)		2006-80025144.6	CN101287453A	16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.		PCT	EPC		6849781.7	EP 1 915 139	16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.		PCX	Hong Kong		8110216.9		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.		PCT	Israel		187431		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.		PCT	Japan		2008-525989		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.		PCT	Mexico		MX/ai/2007/014363		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.		PCT	Norway		20076456		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.		PCT	Singapore		200717796-7		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1104.		PCT	South Africa	2007/09761	2007/09761		16-May-2006	16-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN (VANTIN)
06.1105.		PCT	Australia		20066343445		23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.		PCT	Canada		2611506	2611506	23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.		PCT	China (People's Republic)		200680026985.9		23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.		ORD	EPC		6851355.5	EP 1 937 218	23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.1105.		REP	Hong Kong		8113605.2		16-Dec-2008	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.		PCT	Israel		187567		23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.		PCT	Japan		2008-533328	2008-545808	23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.		PCT	Mexico		MX/a/2007/014764		23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.		PCT	Norway		20076588		23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.	2	DIV	Singapore		1953105		24-Aug-2010	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1105.		PCT	South Africa	2007/10000	2007/10000		23-May-2006	23-May-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A PLATELET AGGREGATION INHIBITOR
06.1901.		PCT	Canada		2612994	2612994	06-Jun-2006	07-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CEFIDITOREN
06.1901.		PCT	EPC		6844139.3	1954253	07-Jun-2006	07-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CEFIDITOREN
06.1901.		PCT	Japan		2008-549464		07-Jun-2006	07-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CEFIDITOREN
06.1903.		PCT	Australia		2006285349		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	Brazil		PI0612297-3		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	Canada		2613474	2613474	19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.	2	DIV	China (People's Republic)		201010209207.1	CN101879140A	21-Jun-2010	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	EPC		6773467.3	EP 1 901 722	19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.1903.		PCT	Eurasian Patent Organization		200800092		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCX	Hong Kong		8110215		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	Israel		188093		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	Japan		2008-518266		20-Dec-2007	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	Korea, Republic of		7001338/2008		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	Mexico		MX/a/2007/016151		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	Norway		20076628		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.	2	DIV	Singapore		1300447		19-Jun-2010		NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.1903.		PCT	South Africa	2007/10715	2007/10715		19-Jun-2006	19-Jun-2026	NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS
06.2001.		ORD	Taiwan		96125474		12-Jul-2007	12-Jul-2027	NANOPARTICULATE FORMULATIONS OF MODAFINIL
06.2003.		ORD	Canada		2684985		31-Aug-2009		COMBINATION OF A NARCOTIC AND NON-NARCOTIC ANALGESIC
06.2003.		PCT	EPC		8732268.1	EP 2 137 182			COMBINATION OF A NARCOTIC AND NON-NARCOTIC ANALGESIC
06.2003.		ORD	PCT		PCT/US2008/057093	WO/2008/115820 A1	14-Mar-2008		COMBINATION OF A NARCOTIC AND NON-NARCOTIC ANALGESIC
06.2025.		PCT	Australia		2007260821		25-Jun-2007	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.		PCT	Canada		2660649		01-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.		PCT	EPC		7799011.7		25-Jun-2007	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.2025.	PCX	Hong Kong		PCT/US2007/072052		25-Jun-2007	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT	Israel		196065		18-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT	Japan		2009-516756		22-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT	Korea, Republic of		7001439/2009		22-Jan-2009	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT	Mexico		MX/a/2008/016223		16-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT	Norway		20090158		02-Feb-2009	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT	Singapore		1748508		04-Dec-2008		COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2025.	PCT	South Africa		2008/10221		02-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
06.2026.	PCT	Australia		2007260822		22-Jan-2009	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
06.2026.	PCT	Canada		2660650		22-Jan-2009	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
06.2026.	ORD	EPC		7784540.2		25-Jun-2007	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
06.2026.	ORD	Israel		196066		18-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
06.2026.	PCT	Japan		2009-516757		22-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
06.2026.	PCT	Korea, Republic of		7001440/2009		22-Jan-2009	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
06.2026.		PCT	Mexico		MX/a/2008/016115		16-Dec-2008	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
06.2026.		PCT	Norway		20090119		22-Jan-2009	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
06.2026.		ORD	Singapore		200808993-0		04-Dec-2008		COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
06.2026.		PCT	South Africa	2008/10098	2008/10098		25-Jun-2007	25-Jun-2027	COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
07.0500.US	2	CON	USA	5332113	07/758,364		10-Sep-1991	26-Sep-2011	CAP ASSEMBLY
07.2005.US	2	ORD	USA		12/757,005		08-Apr-2010		DRUG DELIVERY COMPOSITION (NANO OSMOTIC PUMP)
07.2005.US	3	ORD	USA		12/757,024		08-Apr-2010		CONTROLLED-RELEASE CLOZAPINE COMPOSITIONS
07.2027.US	2	ORD	USA		12/209,728	2009-0149479 A1	12-Sep-2008	12-Sep-2028	DOSING REGIMEN
07.2030.US	4	ORD	USA		12/397,924		04-Mar-2009	04-Mar-2029	STABLE LIQUID FORMULATIONS OF ANTI-INFECTION AGENTS AND ADJUSTED ANTI-INFECTION AGENT DOSING REGIMENS
07.2034.US	2	ORD	USA		12/788,196	US 2010-0316725 A1	26-May-2010	26-May-2030	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
08.2005.		ORD	PCT		PCT/US2010/030387		08-Apr-2010		DRUG DELIVERY COMPOSITION
08.2005.	2	ORD	PCT		PCT/US2010/030393		08-Apr-2010		CONTROLLED RELEASE CLOZAPINE COMPOSITIONS
08.2005.		ORD	Taiwan		99111212		09-Apr-2010		DRUG DELIVERY COMPOSITION
08.2005.	2	ORD	Taiwan		99111214		09-Apr-2010		CONTROLLED-RELEASE CLOZAPINE COMPOSITIONS
08.2027.		PCT	Canada		2697189		19-Feb-2010		DOSING REGIMEN
08.2027.		PCT	EPC		8830097.5	EP 2 197 448	12-Sep-2008		DOSING REGIMEN
08.2027.		PCT	Japan		2010-525030		11-Mar-2010		DOSING REGIMEN
08.2027.		ORD	PCT		PCT/US2008/076189	WO/2009/036287 A1	12-Sep-2008		DOSING REGIMEN
08.2030.		PCT	Australia		2009222020		30-Jul-2010		STABLE LIQUID FORMULATIONS OF ANTI-INFECTION AGENTS AND ADJUSTED ANTI-INFECTION AGENT DOSING REGIMENS
08.2030.		ORD	Taiwan		98106848	200940552	03-Mar-2009	03-Mar-2029	STABLE LIQUID FORMULATIONS OF ANTI-INFECTION AGENTS AND ADJUSTED ANTI-INFECTION AGENT DOSING REGIMENS
08.2034.		ORD	PCT		PCT/US2010/036127	WO/2010/138539	26-May-2010	25-May-2014	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
08.2034.		ORD	Taiwan		99116808		26-May-2010	26-May-2030	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
EMT 04 A		ORD	USA	5242406	07/809,195		16-Dec-1991	16-Dec-2011	DEVICE & METHOD FOR DISPENSING A LIQUID PARTICULARLY USEFUL FOR DELIVERING MEDICAMENTS AT A PREDETERMINED RATE

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
EMT 25		ORD	USA	6312409	09/331,648		07-Sep-1999	07-Sep-2019	DEVICE FOR GENERATING A PULSATILE FLUID DRUG FLOW
EMT 54		DES	USA	D454,194 S	29/135,976		23-Jan-2001	05-Mar-2016	DRUG RECONSTITUTION AND INJECTION DEVICE
EMT BD 13		ORD	Israel	111685	111685		17-Nov-1994	17-Nov-2014	INTRADERMAL DRUG DELIVERY DEVICE
EMT BD 13		PCT	New Zealand	276485	276485		17-Nov-1994	17-Nov-2014	INTRADERMAL DRUG DELIVERY DEVICE
EMT BD 13		ORD	USA	5527288	08/183,482		18-Jan-1994	18-Jan-2014	INTRADERMAL DRUG DELIVERY DEVICE
EMT BD 13	2	CON	USA	5997501	08/647,954		19-Aug-1996	07-Dec-2016	INTRADERMAL DRUG DELIVERY DEVICE
EMT BD 19	2	EPC	Ireland	EP 0 850 076	96931955.7	EP 0 850 076	30-Aug-1996	30-Aug-2016	MEDICAMENT DELIVERY DEVICE
EMT BD 19		EPC	Luxembourg	EP 0 850 076	96931955.7	EP 0 850 076	30-Aug-1996	30-Aug-2016	MEDICAMENT DELIVERY DEVICE
EMT BD 19		EPC	Monaco	EP 0 850 076	96931955.7	EP 0 850 076	30-Aug-1996	30-Aug-2016	MEDICAMENT DELIVERY DEVICE
EMT BD 19		EPC	United Kingdom	EP 0 850 076	96931955.7	EP 0 850 076	30-Aug-1996	30-Aug-2016	MEDICAMENT DELIVERY DEVICE
EMT BD 19		ORD	USA	5814020	08/708,230		06-Sep-1996	06-Sep-2016	MEDICAMENT DELIVERY DEVICE
EMT BD 22	2	ORD	USA	5858001	08/763,311		10-Dec-1996	10-Dec-2016	CARTRIDGE-BASED DRUG DELIVERY DEVICE
EMT 23			United States	US 5871125	08/697,692		5-Sep-2016		Liquid delivery pumping device
EMT BD 24		PCT	Australia	723947	31872/97		04-Jun-1997	04-Jun-2017	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24		PCT	EPC	EP 0 910 420	97927344.8	EP 0 910 420	04-Jun-1997	04-Jun-2017	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24		EPC	France	EP 0 910 420	97927344.8	EP 0 910 420	04-Jun-1997	04-Jun-2017	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24		EPC	Germany	P69718912.0	69718912	EP 0 910 420	04-Jun-1997	04-Jun-2017	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24		ORD	Ireland	80772	960427		10-Jun-1996	10-Jun-2016	DELIVERY NEEDLE
EMT BD 24		EPC	Italy	EP 0 910 420	97927344.8	EP 0 910 420	04-Jun-1997	04-Jun-2017	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24		EPC	United Kingdom	EP 0 910 420	97927344.8	EP 0 910 420	04-Jun-1997	04-Jun-2017	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24		ORD	USA	6261272	09/202,176		01-Jun-1999	04-Jun-2017	NEEDLE FOR SUBCUTANEOUS DELIVERY OF FLUIDS
EMT BD 24	2	CON	USA	6346095	09/778,332		06-Feb-2001	04-Jun-2017	NEEDLE AND METHOD FOR DELIVERY OF FLUIDS
EMT BD 29	2	PCT	Japan		2001-585847		23-May-2001	23-May-2021	SUBCUTANEOUS DRUG DELIVERY DEVICE WITH IMPROVED FILLING SYSTEM
EMT BD 29	2	ORD	USA	6530900	09/577,033		23-May-2000	05-May-2018	SUBCUTANEOUS DRUG DELIVERY DEVICE WITH IMPROVED FILLING SYSTEM
EMT BD 29	3	ORD	USA	6186982	09/072,875		05-May-1998	05-May-2018	SUBCUTANEOUS DRUG DELIVERY DEVICE WITH IMPROVED FILLING SYSTEM
EMT BD 32		ORD	Taiwan	NI-111228	87109549	380046	16-Jun-1998	16-Jun-2018	METHODS OF CALIBRATING AND TESTING A SENSOR FOR IN VIVO MEASUREMENT OF AN ANALYTE AND DEVICES FOR USE IN SUCH METHODS
EMT BD 32		ORD	USA	6275717	09/102,840		23-Jun-1998	23-Jun-2018	METHODS OF CALIBRATING AND TESTING A SENSOR FOR IN VIVO MEASUREMENT OF AN ANALYTE AND DEVICES FOR USE IN SUCH METHODS
EMT BD 33	2	ORD	USA	6000548	09/102,841		23-Jun-1998	23-Jun-2018	DRUG DELIVERY KIT AND METHOD OF PACKAGING THE SAME
EMT BD 36		PCT	Japan	4348011	2000-549327		19-May-1999	19-May-2019	ADHESIVE SYSTEM FOR ATTACHING MEDICAL DEVICES TO A SURFACE
EMT BD 38		EPC	France	EP 1 064 035	99912015.7	EP 1 064 035	23-Mar-1999	23-Mar-2019	DRUG DELIVERY DEVICE
EMT BD 38		EPC	Germany	69913111.1	99912015.7	EP 1 064 035	23-Mar-1999	23-Mar-2019	DRUG DELIVERY DEVICE
EMT BD 38		PCT	Japan	4425465	2000-537590	2002507459	23-Mar-1999	23-Mar-2019	DRUG DELIVERY DEVICE
EMT BD 38	2	ORD	USA	6595956	09/275,464		23-Mar-1999	23-Mar-2019	IMPROVED DRUG DELIVERY DEVICE

Asset Transfer Agreement (EPIL to EDT Pharma Holdings) - 2 August 2011
Schedule 2: Patents

EDT Ref	Sub Case	Case Type	Country	Patent Number	Application Number	Publication Number	Filing Date	Normal Expiry Date	Short Title / Subject Matter
EMT BD 38	3	DIV	USA	7384413	10/461,040	US 2003-0236498 A1	13-Jun-2003	23-Mar-2019	DEVICE FOR MEASURING VOLUME OF DRUG
EMT BD 38	4	DIV	USA		12/121,545		15-May-2008	23-Mar-2019	IMPROVED DRUG DELIVERY DEVICE
EMT BD 38			USA		13/184,479		15-Jul-2011		IMPROVED DRUG DELIVERY DEVICE
EMT BD 38			USA		13/184,473		15-Jul-2011		IMPROVED DRUG DELIVERY DEVICE
EMT BD 45		PCT	Japan	4559627	2000-575564		06-Oct-1999	06-Oct-2019	A METHOD AND DEVICE FOR ENTRAPPING GAS WITHIN A LIQUID DRUG CONTAINER
EMT BD 46		ORD	USA	7530964	09/883,025		17-Jun-2001	03-Oct-2023	NEEDLE DEVICE AND METHOD AND OPERATION THEREOF
EMT BD 50		PCT	Japan		2001-577073		12-Apr-2001	12-Apr-2021	IMPROVED ELECTROLYTIC CELL